The invention relates in general to the field of skin treatment, and more specifically to apparatuses and methods for treating a person's skin.
Abrasion of the outer layer or epidermis of the skin is desirable to smooth or blend scars, blemishes, or other skin conditions that may be caused by, for example, acne, sun exposure, and aging. Standard techniques used to abrade the skin have generally been separated into two fields referred to as dermabrasion and microdermabrasion. Both techniques remove portions of the epidermis called the stratum corneum, which the body interprets as a mild injury. The body then replaces the lost skin cells, resulting in a new outer layer of skin. Additionally, despite the mild edema and erythema associated with the procedures, the skin looks and feels smoother because of the new outer layer of skin.
Dermabrasion refers to a procedure in which the surface of the skin is removed due to mechanical rubbing by a handpiece with an abrasive element that is often in the form of a burr, wheel, or disc. This process tends to be painful and messy. In fact, the procedure is sometimes painful enough to require a local anesthetic. Dermabrasion leaves the skin red and raw-looking. The removed skin can take several months to regrow and heal. Recent efforts have led to the use of lasers instead of abrasive elements, which have resulted in less bleeding, but the pain and mess remains.
Efforts have been made to decrease the mess caused by the process waste, such as removed skin and blood, by adding a suction element. As the process waste is drawn into the suction opening, skin that has not been removed is also pulled against the grit surrounding the suction opening, so the procedure remains fairly messy due to the abrasion that takes place outside of the handpiece by the grit.
Microdermabrasion refers generally to a procedure in which the surface of the skin is removed due to mechanical rubbing by a handpiece emitting a stream of sand or grit. For example, a handpiece can be used to direct an air flow containing tiny crystals of aluminum oxide, sodium chloride, or sodium bicarbonate. The momentum of the grit tends to wear away two to three cell layers of the skin with each pass of the handpiece. Alternatively, new “crystal-free” microdermabrasion techniques utilize a diamond-tipped handpiece without a stream of grit.
Efforts to add a suction element have been more successful in microdermabrasion than in dermabrasion because the handpiece applying the stream of grit is more controllable to a localized area. That is, as the removed skin is drawn into the suction opening, skin that has not been removed is also pulled towards the handpiece where it is treated with the grit stream, allowing for simultaneous local treatment and suction.
Microdermabrasion removes moisture from the skin, so the procedure is always followed by the application of moisturizing creams. However, similar to topical application of moisturizing creams prior to microdermabrasion, the moisturizing elements only work as deep as the active ingredients can passively migrate through the remaining epidermis.
In some embodiments, an apparatus for treating skin has a console with a user input device and a handpiece assembly. The handpiece assembly is configured to treat skin. A fluid line provides fluid communication between the console and the handpiece assembly. A manifold system is coupled to the console and controlled by the user input device, such as a computer, touchscreen, keyboard, and the like. The manifold system is configured to hold releasably a plurality of fluid sources and deliver fluid from at least one of the plurality of fluid sources to the handpiece assembly.
In some embodiments, a tip comprising a skirt portion is configured to couple to a handpiece for treating a target area on a patient's skin. A central body portion is coupled to the skirt portion. A first passage extends through the central body portion and is configured to receive a fluid from the handpiece. At least one second passageway extending through the central body portion and is configured to convey the fluid back into the handpiece. An inner member extends in a generally spiral fashion across at least a portion of a distal face of the central body portion. The inner member defines a channel between the first passage and the at least one second passage. When the tip is place against the skin, a chamber can be formed by the channel and the person's skin.
In some embodiments, a method of treating a target region on a patient's skin comprises providing a tip including a first aperture and at least one second aperture. At least one inner member on the surface of the tip defines at least one channel between the first aperture and the at least one second aperture. An outer member is disposed on the surface of the tip. The outer member engages the target with the tip. A treatment fluid flows distally through the first aperture region and through the at least one channel. The treatment fluid flows proximally through the at least one second aperture.
In some embodiments, a tip comprises a skirt portion configured to couple to a handpiece for treating a target on a patient's skin. A central body portion is coupled to the skirt portion and includes a mounting region substantially opposite the skirt portion. The mounting region configured to receive a pad for treating the skin. A first aperture extends through the skirt portion and the central body portion and configured to receive a fluid from the handpiece. At least one second aperture extending through the skirt portion and the central body portion and configured to convey the fluid back into the handpiece.
In some embodiments, a method of treating a target region of a patient comprises providing a tip including a first aperture, at least one second aperture, and a distal end configured to receive a pad. In some variations, the first pad is attached to the distal end. The tip is engaged with the target region.
In some embodiments, a manifold system comprises a body portion configured to receive releasably at least two bottles. The manifold is configured so that it can be coupled to a console. The console includes a handpiece for treating skin. At least one elongate member is in communication with a pump and configured to extract a fluid from one of the at least two bottles. At least one switch is configured to permit or inhibit a flow of the fluid from one of the at least two bottles through the pump. In some variations, the elongate member is dimensioned to fit within one of at least two bottles to draw fluid out of the bottle.
In some embodiments, a method of treating a target region on a patient's skin comprises engaging a tip with the patient's skin such that an effective amount of skin is removed by the tip. In some variations, the tip is a dry tip. After removing an effective amount of skin, another tip (e.g., a wet tip) engages the patient's skin such that an effective amount of skin is removed by the tip. In some variations, acid is delivered out of the wet tip to facilitate skin removal. In some variations, the wet tip includes a first aperture, at least one second aperture, at least one inner member on the surface of the tip defining at least one channel between the first aperture and the at least one second aperture, and an outer member on the surface of the tip. In some variations, treatment fluid flows outwardly along the channel. In some variations, treatment fluid flows inwardly along the channel. In some variations, the wet tip comprises an abrasive pad.
In some embodiments, a method of treating a target region on a patient's skin comprises engaging a first skin treatment tip with the patient's skin. A first material is delivered out of the first skin treatment tip to a target region. A second skin treatment tip engages the target region while the first material effectively facilitates exfoliation with the second skin treatment tip. In some variations, the first material comprises an acid, hydrator, and combination thereof. In some variations, the first skin treatment tip is configured to remove skin at a different rate than the second skin treatment tip. In some variations, the first skin treatment tip is configured to exfoliate at a higher rate than the second skin treatment tip. In some variations, material is delivered out of the second treatment tip to the target region of the patient's skin.
The apparatus for treating skin can dispense treatment material that is held in containers, such as bottles, bags, pouches, or other suitable structures for holding and storing material. These containers can be non-refillable or refillable. The treatment material can be delivered by gravity feed, pumps, or suction devices. The manifold system can be used to control fluid flow from a plurality of containers to one or more handpieces.
Having thus summarized the general nature of the invention, certain preferred embodiments and modifications thereof will become apparent to those skilled in the art from the detailed description herein having reference to the figures that follow.
As explained in more detail below, the handpiece assembly 18 is applied to the target area of the patient to perform skin treatment(s). As used herein, the term “skin treatment” is a broad term and includes, but is not limited to, skin removal, skin abrasion (e.g., dermabrasion, microdermabrasion, etc.), ablating or slicing skin (preferably a thin layer of skin), stimulation (including thermal, mechanical, electrical, and/or chemical stimulation), mesotherapy, isophoresis, light therapy, vacuum therapy, and the like. Preferably, the handpiece assembly 18 administers a treatment material from at least one of the containers 26 through the line 20 to the target area of the skin while the handpiece assembly 18 engages the skin.
As used herein, the term “treatment material” is a broad term and includes, but is not limited to, medicament, a substance tending to flow or conform to the outline of its container such as fluid, gas, liquid (e.g., serums, water, saline, etc.), gel, fluidized material, additives, and/or a plurality of fine solids. The general term “fluid” is used throughout synonymously with the term “treatment material” and is to be given the same broad definition. The handpiece assembly 18 can preferably massage, abrade, ablate, or otherwise treat the target skin area while also applying a treatment material to the patient. In certain embodiments, the treatment material and tip of the handpiece 18 can work in combination for an effective and rapid skin treatment. Additionally, any number of “dry” and “wet” tips can be used alone or in combination for treatment flexibility.
With continued reference to
The distal end 22 of the line 20 is connected to the handpiece assembly 18. Preferably, the line 20 includes a filter 28 that removes contaminants or impurities from the treatment material passing through the line 20. In other embodiments, the filter 28 is located in the console 12 or the manifold system 24. The console 12 can be connected to a power source such as an AC outlet. The power source can power the handpiece assembly 18 and/or other components of the skin treatment system 10, such as, for example, pumps, valves, and the like.
In the illustrated embodiment, the console 12 comprises four casters 33 to allow for easy movement, for example, from one treatment room to another treatment room. In such an embodiment, the console 12 can be conveniently rolled on a support surface. Other means of transportation can also be employed or the console 12 can be stationary. In some embodiments, the console 12 is portable for convenient transport.
The illustrated containers 26 of
Multiple handpieces assemblies 18 and/or tips 34 can be used during a single skin treatment procedure in a wet and/or dry mode of operation. For example, a first handpiece assembly 18 may be employed to treat a patient's face and neck while a second handpiece assembly 18 may be employed to treat other larger areas of the patient's body. Thus, different handpieces 18 can be used to treat different regions of a person's body. The configurations of the handpieces 18 and tips can be selected based on the treatment material to be applied, desired interaction with the patient's skin, size of treatment area, skin condition, and the like.
With reference to
The main body 30 has contoured portions 70 at its distal end 36 so that the user can comfortably grip the handpiece assembly 18 during use. The main body 30 can have other designs to provide a comfortable grip.
As noted above, the tip 34 can be pressed against a patient's skin to perform a skin treatment. The distal end 102 of the tip 34 may be angled with respect to the handpiece assembly 18 to increase the contact area with the patient's skin without enlarging the handpiece assembly 18 for an ergonomic and comfortable design. The angled tip 34 can lay flat on the skin while the main body 30 is angled to the skin. The angle between the face of the distal end 102 and the longitudinal axis of the handpiece assembly 18 can be selected based on the desired size of the face of the distal end 102. In alternative embodiments, the face of the distal end 102 is generally perpendicular to the longitudinal axis of the main body 30.
The tip 34 can be permanently or temporarily coupled to the distal end 36 of the main body 30. In some embodiments, the tip 34 is disposable. As used herein, the term “disposable,” when applied to a system or component (or combination of components), such as a tip, container, or pad, is a broad term and means, without limitation, that the component in question is used a finite number of times and then discarded. Some disposable components are used only once and then discarded. Other disposable components are used more than once and then discarded. In some embodiments, the tip 34 is removably coupled to the main body 30 such that the tip may be removed from the main body 30 and thrown away to avoid cross-contamination. In other embodiments, the tip 34 is a reusable tip that can be cleaned, for example by autoclaving, after each use. The tip 34 can thus be used for any number of procedures as desired.
With reference to
The input line 52 delivers treatment material from at least one of the containers 26 to the connector 46. The fluid then flows through the main body 30 and ultimately to the tip 34. As shown in
To treat the person's skin 80, the handpiece assembly 18 can also be moved relative to the skin 80 such that the tip 34 maintains engagement with the skin 80. The illustrated tip 34 is configured to massage the skin 80 while also providing fluid communication with the skin 80. As detailed below in connection with
When the tip 34 and treatment material are used in combination, the handpiece assembly 18 preferably exfoliates dead skin cells and extracts impurities by applying a vacuum while simultaneously bathing the healthy underlying skin with active treatment material. The active treatment material can facilitate cleansing, exfoliating, hydrating, and/or provide residual antioxidant protection. The treatment material and tip 34, alone or in combination, can effectively and rapidly treat the target skin area. The waste material, including the used treatment material, removed skin, and/or grit, can then be drawn back through the tip 34, the main body 30 via lumen 90, and into the connector 44. The waste then flows into the output line 50 for subsequent disposal, as detailed below in connection with
In some embodiments, including the illustrated embodiment of
The intermediate chamber 116 can be interposed between the through-holes 114 and the lumen 90. The intermediate chamber 116 is preferably defined by the distal face 43 of the main body 30 and the proximal face 41 of the tip 34. The intermediate chamber 116 can provide equalization of fluid between the tip 34 and the body 30. As such, a generally equal vacuum is applied to both through-holes 114. The fluid can flow through the through-holes 114, into the intermediate chamber 116, and then into the lumen 90. In some embodiments, however, the fluid flows directly from the through-holes 114 to the lumen 90 without passing through an intermediate chamber 116.
The tip 34 can have one or more sealing members to form a fluidic seal between the tip 34 and the main body 30. The illustrated main body 30 includes a sealing member 47 that engages the inner surface of the skirt 64 of the tip 34. The sealing member 47 can be a compliant member comprising rubber, polymer, plastic, or other suitable material for forming seals. In some embodiments, the sealing member 47 is an O-ring made of rubber.
With continued reference to
In alternative embodiments, the fluid flows in the opposite direction. That is, the line 50 delivers fluid through the lumen 90 into the tip 34. The fluid flows through the intermediate chamber 116 and the through-holes 114. The fluid then flows to the chamber 100 and inwardly through the tip connector 98 to the lumen 92. The fluid proceeds proximally along the lumen 92 and ultimately into the line 52.
In yet another embodiment, the handpiece assembly 18 comprises two or more input lumens 90. Such a design allows mixing of two or more treatment materials within the handpiece assembly 18 or space 100, which would be useful for treatments with fluids that react or are unstable or degrade when stored or mixed.
As depicted in
The illustrated controller 60 is a generally cylindrical body that is pivotally connected to the main body 30.
The handpiece assembly 18 can also include one or more flow rate controllers within the main body 30 that cooperate with the controller 60 to adjust the fluid flow out of the tip 34. For example, the controller 60 may comprise a flow control valve such as a globe valve, butterfly valve, needle valve, or variable orifice. Other types of flow rate controllers can also be used, such as an electrically controlled solenoid valve. In embodiments where the fluid flow is electronically controlled, the valve system may alternatively be located in the console 12 or manifold system 24. Separate devices can also be used to control the flow of treatment material. For example, clamps, pinch valves, or other suitable devices can be used to control fluid flow through the lines 50, 52.
Various types of tips 34 can be used with the handpiece assemblies 18 illustrated in
As shown in
With respect to
The inner member 124 is preferably spaced from the outer member 120 to define one or more channels. The illustrated outer member 120 defines a continuous channel 140 that extends outwardly from the central through-hole 122 towards at least one of the outer through-holes 114. The inner member 120 can form the sidewalls of the channel 140. Any suitable configuration of channels 140 can be used to provide fluid flow along a flow path. The illustrated channels 140 have a somewhat U-shaped axial cross-sectional profile, as depicted in
The spiral-like pattern of the inner members 124 in
Additionally, the inner members 124 can be configured to remove tissue. The inner member 124 can be an abrasive member designed to remove tissue when the inner member 124 slides along a person's skin. The user may select a tip 34 based on the appropriate detention time and abrasiveness for the treatment being applied. For example, the tip 34 illustrated in
The illustrated tip 34 includes a generally continuous inner member 124 that extends from near the through-hole 122 towards at least one of the through-holes 114. In other embodiments, the tip 34 can have a plurality of inner members 124. For example, the inner members 124 can be linear, curved, and may be continuous or discontinuous.
The handpiece assembly 18 can be moved while the spiral-like inner member 124 engages the patient's skin. The movement of the handpiece assembly 18 can increase the effectiveness of the treatment material expelled out of the tip 34. In some embodiments, for example, the tip 34 can be used with a lifting treatment material that facilitates extractions of, for example, sebum, blackheads, skin, or other substances (e.g., oils, dead skin, etc.). The lifting treatment extraction producer can unclog pores to improve the treated skin's overall appearance. To facilitate extractions, the handpiece assembly 18 can be twisted or rotated while the tip 34 is pressed against the patient's skin. The twisting action and the lifting treatment material can work in combination for effective extractions. In alternative embodiments, a handpiece assembly 18 can also be used without a lifting treatment material for extractions by employing the twisting motion.
In certain embodiments, the spiral-like tip 34 massages the skin 80. In other embodiments, the spiral-like tip 34 ablates the skin 80. For example, the inner members 124 may act as blades to cut thin layers from the skin 80 when the user twists the handpiece assembly 18. Twisting the handpiece assembly 18 causes the tip 34 to rotate about the twisting axis, rotating the sharp inner members 124 against the skin 80, which causes ablation. Thin layers of skin can thus be removed by the handpiece assembly 18. Additionally or alternatively, the spiral-like tip 34 may plane along skin when a fluid is applied to the skin. The planing tip 34 can remove a thin layer of the skin (e.g., the stratum corneum, preferably hydrated stratum corneum). Accordingly, the user can use the handpiece assembly 18 to remove a particular amount of skin.
A vacuum can be applied by the handpiece assembly 18. For example, the console 12 can have a pump that applies a vacuum via the output line 52. The negative pressure draws waste material into the through-holes 114 and out of the handpiece assembly 18. When the tip 34 engages the patient's skin, the vacuum can draw the skin against the tip 34 to enhance the effectiveness of the inner members 124. The vacuum can be increased or decreased to increase or decrease, respectively, for example, frictional forces, depth of cutting, amount of abrasion, and the like. To rapidly remove skin, a strong vacuum can be applied to the person's skin so that the skin is pulled against the inner member 124. The vacuum can also facilitated removal of the waste fluid captured between the tip 34 and the patient's skin. A vacuum can also be used in combination with the tips illustrated in
The tip 34 can have any suitable number of through-holes 114, 122 to achieve the desired fluid flow between the skin 80 and the tip 34. For example,
The tips can also have one or more energy sources for delivering energy to the skin. Radiant energy, heat, and the like can be delivered to the skin by the tips. The tip 34 illustrated in
In alternative embodiments, the tips can carry deployable material. The structure 151 can be in the form of a cavity or pocket that contain and carry material that is released when it engages the treatment fluid. The material in the cavities 151 can be made of any of the treatment materials disclosed herein, and can be in a solid form. For example, the cavities can hold lubricant or soap that is released when the tip is applied to skin.
The protruding member 124 can optionally contain treatment material. For example, the protruding members 124 can be generally cylindrical members having a passageway or chamber 127 that holds treatment material. Thus, fluid can be used in combination with treatment material coupled to the tip 34.
With reference to
The pad 128 preferably has a distal surface 224 configured to treat a person's skin. In some embodiments, the pad 128 is a disposable pad that comprises treatment material attached thereto. For example, the pad 128 may comprise vitamins, moisturizers, antioxidants, and the like. Preferably, the pad 128 comprises an adhesive proximal side and a distal side 224 including an abrasive surface. The abrasive surface can have grit, a plurality of members (e.g., members similar to the inner members 124 described above), or the like. The pad 128 can be permanently coupled to the mating surface 227 so that the tip 34 can be used for an extended length of time, or for multiple treatments. In alternative embodiments, the tip 34 is removable for maximum flexibility in selecting pad abrasiveness, and also allows the user to make changes to the tip 34 without changing the tip 34 in its entirety. The grit rating of abrasive surface of the distal surface 224 can be selected based on the desired rate of skin removal.
The illustrated pad 128 is generally elliptical and planar. In alternative embodiments, the pad 128 can be polygonal, circular, or have any other shape as desired. The pad 128 can have cutouts 225 that can match the through-holes 114, 122. The cutouts 225 can be aligned with the through-holes 114, 122 when the pad 128 is coupled to the mounting surface 227 of the tip 34, as shown in
Various types of adhesives can be used to temporarily or permanently couple the pad 128 to the mounting surface 227. As used herein, the term “adhesive” is a broad term and includes, but is not limited to, coupling agents, glues, bonding materials, or the like. In some embodiments, for example, waterproof pressure sensitive adhesives are used for releasably coupling the pad 128 to the mounting surface 227. In some embodiments, the pad 128 can be permanently coupled to the mounting surface 227. For example, the pad 128 can be bonded or fused to the main body 66. Additionally or alternatively, snap fittings, fasteners, or other coupling structures can be used to mount the pad 128.
The tip 34 described above can be used for wet or dry modes of operation. As such, the tip 34 can be used for wet exfoliation or dry exfoliation. In some embodiments, the tip 34 is used in a dry mode to remove a desired amount of skin. After removing a desired amount of skin, the tip 34 can be used in a wet mode on the same or different area of the patient's kin. During wet mode, fluid can be passed out of the tip 34 onto the patient's skin. The wet tip 34 can exfoliate, hydrate, and/or perform other types of treatments. Alternatively, the tip 34 can be used in a wet mode and than a dry mode. The sequence of wet and dry modes of operation can be selected based on the type of tip, treatment material, skin condition, and the like.
Although the handpiece assemblies are primarily discussed with respect to use with treatment material, the handpiece assemblies can be used without treatment material, i.e., the handpieces can be used in a dry procedure. Dry procedures can be used for non-hydration procedures and may require less post-procedure clean up.
Various fabrication techniques can be employed to make the tips 34 as mentioned above in connection with
The tips 34 can also be fabricated in a multi-step process. For example, the main body 66 and skirt 64 can be formed in a single process. A textured surface (e.g., pad, inner members 124, etc.) can be applied to the main body 66 in a subsequent process. The textured surface can be formed by cutting, embossing, adding material (e.g., a pad, adhesive grit, etc.), a roughening implement, stamping process, or other suitable texturing means.
The tips can have associated treatment materials, including, for example, a medicament. As used herein, the term “medicament” is a broad term and includes, without limitation, growth agents, growth factors or hormones, growth inhibitors, serums, treatment material, cleaners, vitamins, exfoliators, lubricants, or other substances that can be used to treat a patient's skin. The medicament can be associated with the tip 34 by imbedding, overlaying, coating, impregnation, co-mixing, absorption, or other suitable means for associating the medicament with the tip 34. The medicament can be hardened so that it can further enhance massaging and/or abrasion. In some embodiments, the medicament forms hardened grit that can be imbedded on the surface of the tip 34. The grit can work in combination with the inner members 124 to treat a person's skin. If a fluid is used, the fluid can facilitate the release of the medicament from the tip 34. In some embodiments, the medicament comprises or more bioactive substances, such as antibiotics, substances for accelerating the healing of the wound, cell proliferation agents, and the like. Such bioactive substances may be desirable because they contribute to the healing of damaged or removed skin, as well as reducing the likelihood of infection.
The inner members 124 of
Referring again to
As shown in
Bodies 262 of the containers 26 may be formed by stretch blow molding a preform into the desired shape. In other embodiments, the body 262 and a neck 264 can be formed by extrusion blow molding. For example, the bottle of
In some embodiments, including the illustrated embodiment of
In either of the embodiments illustrated in
The insertion tip assembly 59 has an elongate member 161 that comprises a fluid pick up conduit 62 and lancing tip 64 extending from the distal end of the conduit 62. In the illustrated embodiment, the lancing tip 64 is a tubular member having a somewhat sharp distal end. To access treatment fluid in the bottle 26, the lancing tip 64 can be inserted into the closure passageway 73 of the closure 266. The lancing tip 64 can be advanced through the passageway 73 until it breaks the sealing member 267. The elongate member 161 can be sufficiently rigid such that it can break the sealing member 267 without buckling. The elongate member 161 can comprise metal, polymers, plastics, or any suitable material.
The fluid pick up conduit 62 and lancing tip 64 can be slid through the passageway 73 until the stop 91 is spaced from the upper edge of the closure 266. In alternative embodiments, the insertion tip assembly 59 can be slid through the passageway 73 until the stop 91 contacts the upper edge of the closure 266, as shown in
In certain embodiments, the treatment fluid applied from the containers 26 may be selected from the console 12 for a particular treatment or skin type. In one embodiment, the treatment fluid may comprise a skin rejuvenation serum. Skin rejuvenation serum cleans the skin 80 deeply while softening sebum and impurities to aid in extractions. Skin rejuvenation serum also assists in dislodging dead cells for extraction and exfoliation by the tip 34 as well as providing residual hydration that aids in firming and smoothing fine lines, resulting in clean, refined, and ultra-moisturized skin 80. Preferably, a skin rejuvenation treatment serum is active-4™, available from Edge Systems Corp., 2277 Redondo Ave., Signal Hill, CA, 90755, (800) 603-4996. In another embodiment, the treatment fluid may comprise a salicylic acid serum. A salicylic acid serum cleans oily skin deeply while softening sebum and impurities to aid in extraction and exfoliation by the tip 34. Hydration additives in the salicylic acid serum create an ultra-moisturized skin surface, and is blended to remain on the face for the best possible benefit. Preferably, a salicylic acid treatment fluid is beta-hd™, also available from Edge Systems Corp. In yet another embodiment, the treatment fluid may comprise antioxidants. The antioxidant serum is a hybrid that combats free radicals and environmental damage to the cells. The antioxidant serum is formulated with a blend of the most effective antioxidant ingredients. The antioxidant serum is an absorbable, leave-on service that improves the appearance of age signs as well as texture and clarity. Preferably, an antioxidant treatment fluid is antiox-6™ also available from Edge Systems Corp. The treatment fluids may comprise agents known to be beneficial to skin healing and/or hydration including but not limited to glucosamine, laminaria digitata extract, yeast extract, carbamide, lactic acid, sodium lactate, honey extract, pentylene glycol, spirea ulmaria extract, Camellia sinensis leaf (white tea) extract, horse chestnut extract, stabilized vitamins A, B1, B6, B12, C, and E, tocopherol, inositol, calcium panthothenate, linoleic acid, rosemarinus officinalis extract, biotin, and aloins such as anthraquinone gycosides, polysaccharides, sterols, gelonins, and chromones.
A single treatment may comprise the serial use of several treatment fluids from the containers 26. For example, the treatment of acne prone skin may comprise salicylic treatment followed by antioxidant treatment, the treatment of aging skin may comprise skin rejuvenator treatment followed by salicylic treatment followed by antioxidant treatment, the treatment of congestion (e.g., blackheads) may comprise skin rejuvenator treatment followed by salicylic treatment followed by antioxidant treatment, the treatment of damaged skin (e.g., due to medication or smoking) may comprise skin rejuvenator treatment followed by antioxidant treatment, the treatment of skin may comprise skin rejuvenator treatment followed by salicylic treatment followed by antioxidant treatment, the treatment of hyperpigmentation may comprise skin rejuvenator treatment followed by salicylic treatment followed by antioxidant treatment, the treatment of melasma may comprise skin rejuvenator treatment followed by salicylic treatment followed by antioxidant treatment, the treatment of sensitive skin may comprise skin rejuvenator treatment followed by antioxidant treatment, and the treatment of thin skin may comprise salicylic treatment followed by antioxidant treatment. Alternatively, a single treatment may comprise the parallel use of a combination of treatment fluids from the containers 26, for example using a handpiece with a plurality of input lumens 90 as described above. Treatment time with each treatment fluid is preferably about 2 to 20 minutes, but may be longer or shorter depending on the patient, the tip 34 used, and the treatment itself.
The treatment materials can be used for acne (e.g., by removing oils, bacteria, etc.), melasma, damaged skin (e.g., sun damaged skin, burns, free radical damage, etc.), extractions, skin lightening and/or brightening, skin lines (e.g., fine lines, wrinkles, creases, etc.), dry skin, and the like. The treatment materials can improve skin elasticity and overall health of the skin. For example, if the skin is damaged, antioxidants can be applied to damaged area. Accordingly, the skin treatment system 10 can be used to improve the health, appearance, and/or function of a person's skin.
Additionally, the line 20 may be periodically flushed with a fluid (e.g., a antimicrobial fluid, water, etc.) contained in one of the containers 26. Antimicrobial fluids can contain any disinfecting agent compatible with skin including, but not limited to, butylene glycol, phenoxyethanol, and methyl isothiazolinone. Preferably, an antimicrobial fluid is Rinseaway™, available from Edge Systems Corp. The line 20 should be flushed with antimicrobial fluid at least at the end of each service day. Flushing with antimicrobial fluid is more important when the system is not used for consecutive days.
As illustrated in
With continued reference to
To couple the bottle 26 to the manifold system 24, the closure 266 can be inserted through the aperture 317 of the slide structure 249 when the button 246 is pushed in. Once the closure 266 engages the stop surface 333 (
The manifold system 24 can have a modular design so that it can be removed from the console 12. In some embodiments, the manifold system 24 and associated containers 26 can be removed and transported away from the console 12. Accordingly, the modular manifold systems can be interchanged to provide treatment flexibility. Alternatively, the manifold system 24 can be permanently mounted to the console 12.
In certain embodiments, including the embodiment of
The console 12 can also comprise a mechanical system for controlling fluid flow from the containers to the handpiece. One or more pumps, valves, fluid lines, and the like can cooperate to deliver fluid from the containers to the handpiece. The console 12 can be powered pneumatically, electrically, or by any other suitable powering means. The mechanically drive console 12 can have manual controls for controlling fluid flow to the handpiece.
The console 12 can also comprise additional handpieces suitable for other types of skin treatment. These additional handpieces can be used for pre-treatment or post-treatment in combination with other modalities. For example, the console 12 may include a handpiece for diamond tip abrasion, or “crystal-free” microdermabrasion, as described above. Such a handpiece may be useful for more aggressive treatments, in addition to treatment with the handpiece assembly 18. The diamond tips can range from fine to extra coarse.
In some embodiments, the console 12 comprises a handpiece including at least one light emitting diode (LED). Light therapy has been shown to improve skin. For example, red light between about 600 and about 700 nanometers and infrared LED light between about 700 and about 1,000 nanometers reduces the appearance of fine lines and superficial hyperpigmentation. For another example, blue LED light at about 430 nanometers improves the appearance of oily and acne-prone skin. Other benefits of light therapy include promotion of collagen production, increased circulation and moisture retention, smoothing of skin texture, and improvement of skin firmness and resilience.
The console 12 can comprise handpieces for vacuum therapy such as lymphatic drainage and cellulite massage. Vacuum therapy enhances the effects of treatment with the handpiece assembly 18 and LED light therapy. Preferably, the vacuum therapy handpieces are sized appropriately for facial massage and body massage. An example of a multi-modality protocol using a plurality of handpieces comprises diamond tip abrasion, treatment with handpiece assembly 18 and at least one treatment fluid from containers 26, vacuum therapy, red light therapy, and application of sunscreen, for example at a minimum skin protection factor (SPF) of 15. The various modalities may be included and ordered by the user depending on the desired outcome of the overall treatment.
The console 12 optionally includes any of a plurality of additional features. For example, a digital camera may be used to take pictures of the patient before and after treatment, and the pictures may be stored on the computer. The computer may hold client medical and treatment records. The computer may be connected to a network. The console 12 may store disks. The console 12 may include an ultrasound unit. The console 12 may include a stimulator, such as an electrical stimulator. The console 12 may include an iontophoresis handpiece. The number of additional features is limitless when considering the range of features that a user may wish to incorporate with the treatment provided by the handpiece assembly 18.
The line 20 includes an output line 50 for removing waste from the handpiece assembly 18 and an input line 52 for delivering treatment material to the handpiece assembly 18. A valve 300 can be disposed along the input line 52 to inhibit backflow of treatment material. The console 12 can pump treatment material through the input line 52 to the handpiece assembly 18 when the handpiece assembly 18 is applied to the person's skin, as detailed above. The fluid flow through the input line 52 can be reduced or stopped so that the handpiece assembly 18 can be removed from the patient's skin. The valve 300 can inhibit the flow of fluid through the input line 52 towards the console 12. A desired amount of treatment material can therefore be contained in the handpiece assembly 18 and the section 310 of the input tubing 52 extending between the valve 300 and the handpiece assembly 18. When the handpiece assembly 18 is applied to a patient's skin, a vacuum can be applied to the output line 50. The vacuum can draw the treatment material out of the handpiece assembly 18 without a substantial or noticeable delay.
In some embodiments, the valve 300 can be a one-way valve, such as a duckbill valve, check valve, or other type of valve for inhibiting fluid flow. In alternative embodiments, the valve 300 can comprises a plurality of valves (e.g., one-way valves, flow regulators, adjustable valves, etc.).
In some embodiments, the section 310 of the output line 50 has a length L greater than 6 inches, 12 inches, 18 inches, 24 inches, and ranges encompassing such lengths. In some embodiments, the section 310 of the output line 50 has a length L greater than 24 inches, 30 inches, 36 inches, and ranges encompassing such lengths. The passageway 312 can have a cross-sectional area that is at least 10%, 30%, 50%, 75%, or 100% greater than the cross-sectional area of the passageway 314. The length L and the diameters of the passageways 312, 314 can be selected based on the desired amount of treatment material to be stored in the line 20, delivery and removal rates.
In operation, the cartridge 362 can be inserted into the main body 30. The handpiece assembly 360 can be applied to a patient's skin to deliver treatment material from the cartridge 362 to the patient's skin. After delivering a desired amount of treatment material, the cartridge 362 can be separated from the main body 30. The cartridge 362 can be a one-use or multi-use cartridge. For example, the cartridge can be a non-refillable disposable cartridge.
The tip 34 can also be used to remove hair or perform other skin treatments. For example, the tip 34 can include one or more razor blades and may be configured to apply a treatment material (e.g., antioxidents, vitamins, serums, growth agents, etc.) to the skin during the shaving process. In such embodiments, the main body 30 can be an elongated handle that is connected to a transversely extending elongate tip 34. In some embodiments, the handpiece assembly can be in the form of a disposable handheld razor. The treatment material can reduce or substantially eliminate problems associated with wet or dry shaving systems. These treatment materials may be applied prior to, during, before, and/or after shaving.
The articles disclosed herein may be formed through any suitable means. The various methods and techniques described above provide a number of ways to carry out the invention. Of course, it is to be understood that not necessarily all objectives or advantages described may be achieved in accordance with any particular embodiment described herein. Thus, for example, those skilled in the art will recognize that the methods may be performed in a manner that achieves or optimizes one advantage or group of advantages as taught herein without necessarily achieving other objectives or advantages as may be taught or suggested herein.
Furthermore, the skilled artisan will recognize the interchangeability of various features from different embodiments disclosed herein. Similarly, the various features and steps discussed above, as well as other known equivalents for each such feature or step, can be mixed and matched by one of ordinary skill in this art to perform methods in accordance with principles described herein. Additionally, the methods which are described and illustrated herein are not limited to the exact sequence of acts described, nor are they necessarily limited to the practice of all of the acts set forth. Other sequences of events or acts, or less than all of the events, or simultaneous occurrence of the events, may be utilized in practicing the embodiments of the invention.
Although the invention has been disclosed in the context of certain embodiments and examples, it will be understood by those skilled in the art that the invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses and obvious modifications and equivalents thereof. Accordingly, it is not intended that the invention be limited, except as by the appended claims.
This is a continuation of U.S. patent application Ser. No. 18/094,884 filed Jan. 9, 2023 and issued as U.S. Pat. No. 11,865,287 on Jan. 9, 2024, which is a continuation of U.S. patent application Ser. No. 17/165,820 filed Feb. 2, 2021 and issued as U.S. Pat. No. 11,547,840 on Jan. 10, 2023, which is a continuation of U.S. patent application Ser. No. 16/517,268 filed Jul. 19, 2019 and issued as U.S. Pat. No. 11,446,477 on Sep. 20, 2022, which is a continuation of U.S. patent application Ser. No. 15/660,750 filed Jul. 26, 2017 and issued as U.S. Pat. No. 10,357,641 on Jul. 23, 2019, which is a continuation of U.S. patent application Ser. No. 14/700,789 filed Apr. 30, 2015 and issued as U.S. Pat. No. 9,814,868 on Nov. 14, 2017, which is a continuation of U.S. patent application Ser. No. 13/267,554 filed Oct. 6, 2011 and issued as U.S. Pat. No. 9,474,886 on Oct. 25, 2016, which is a continuation of U.S. patent application Ser. No. 11/392,348 filed Mar. 29, 2006 and issued as U.S. Pat. No. 8,048,089 on Nov. 1, 2011, which claims the benefit of U.S. Provisional Application No. 60/755,310 filed Dec. 30, 2005 and U.S. Provisional Application No. 60/764,668 filed Feb. 2, 2006. The entireties of all of the aforementioned applications are hereby incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
1651585 | Clair | Dec 1927 | A |
D117295 | Smith | Oct 1939 | S |
D151807 | Berkowitz | Nov 1948 | S |
2608032 | Garver | Aug 1952 | A |
2631583 | Lavergne | Mar 1953 | A |
2701559 | Cooper | Feb 1955 | A |
2712823 | Kurtin | Jul 1955 | A |
2867214 | Wilson | Jan 1959 | A |
2881763 | Robbins | Apr 1959 | A |
2921585 | Schumann | Jan 1960 | A |
3037509 | Schutz | Jun 1962 | A |
3085573 | Meyer et al. | Apr 1963 | A |
3214869 | Stryker | Nov 1965 | A |
3468079 | Kaufman | Sep 1969 | A |
3476112 | Elstein | Nov 1969 | A |
3481677 | Abrahamson | Dec 1969 | A |
3505993 | Lewes et al. | Apr 1970 | A |
3560100 | Spatz | Feb 1971 | A |
3574239 | Sollerud | Apr 1971 | A |
3608553 | Balamuth | Sep 1971 | A |
3715838 | Young et al. | Feb 1973 | A |
3865352 | Nelson et al. | Feb 1975 | A |
3866264 | Engquist | Feb 1975 | A |
D237776 | Arassa et al. | Nov 1975 | S |
D237863 | Peters et al. | Dec 1975 | S |
3930598 | Slagle | Jan 1976 | A |
3948265 | Al Ani | Apr 1976 | A |
3964212 | Karden | Jun 1976 | A |
3968789 | Simoncini | Jul 1976 | A |
3977084 | Sloan | Aug 1976 | A |
4121388 | Wilson | Oct 1978 | A |
4155721 | Fletcher | May 1979 | A |
4170821 | Booth | Oct 1979 | A |
4182329 | Smit et al. | Jan 1980 | A |
4203431 | Abura et al. | May 1980 | A |
D255325 | Hoyt | Jun 1980 | S |
4216233 | Stein | Aug 1980 | A |
4225254 | Holberg et al. | Sep 1980 | A |
D258348 | Hoyt | Feb 1981 | S |
D259921 | Hartmann | Jul 1981 | S |
D260176 | Boschetti et al. | Aug 1981 | S |
4289158 | Nehring | Sep 1981 | A |
4299219 | Norris, Jr. | Nov 1981 | A |
4342522 | Mackles | Aug 1982 | A |
4378804 | Cortese | Apr 1983 | A |
4500222 | Clading-Boel | Feb 1985 | A |
4560373 | Sugino et al. | Dec 1985 | A |
D288293 | Arvans | Feb 1987 | S |
4646480 | Williams | Mar 1987 | A |
4646482 | Chitjian | Mar 1987 | A |
4655743 | Hyde | Apr 1987 | A |
4671412 | Gatten | Jun 1987 | A |
4676749 | Mabille | Jun 1987 | A |
D290999 | Novak | Jul 1987 | S |
4706676 | Peck | Nov 1987 | A |
4718467 | Di Gianfilippo et al. | Jan 1988 | A |
4754756 | Shelanski | Jul 1988 | A |
4757814 | Wang et al. | Jul 1988 | A |
4764362 | Barchas | Aug 1988 | A |
4795421 | Blasius, Jr. et al. | Jan 1989 | A |
4811734 | McGurk-Burleson et al. | Mar 1989 | A |
4836192 | Abbate | Jun 1989 | A |
4866202 | Weil | Sep 1989 | A |
4875287 | Creasy et al. | Oct 1989 | A |
4886078 | Shiffman | Dec 1989 | A |
4887994 | Bedford | Dec 1989 | A |
4900316 | Yamamoto | Feb 1990 | A |
4917086 | Feltovich et al. | Apr 1990 | A |
4925450 | Imonti et al. | May 1990 | A |
D308480 | Hoyt | Jun 1990 | S |
4940350 | Kim | Jul 1990 | A |
4957747 | Stiefel | Sep 1990 | A |
4990841 | Elder | Feb 1991 | A |
5006004 | Dirksing et al. | Apr 1991 | A |
5006339 | Bargery et al. | Apr 1991 | A |
5012797 | Clarke | May 1991 | A |
D317719 | Hestehave et al. | Jun 1991 | S |
5035089 | Tillman et al. | Jul 1991 | A |
5037431 | Summers et al. | Aug 1991 | A |
5037432 | Molinari | Aug 1991 | A |
5054339 | Yacowitz | Oct 1991 | A |
5100412 | Rosso | Mar 1992 | A |
5100424 | Jang | Mar 1992 | A |
5119839 | Rudolph | Jun 1992 | A |
5122153 | Harrel | Jun 1992 | A |
5171215 | Flanagan | Dec 1992 | A |
5192269 | Poli et al. | Mar 1993 | A |
5207234 | Rosso | May 1993 | A |
5217455 | Tan | Jun 1993 | A |
5222956 | Waldron | Jun 1993 | A |
5242433 | Smith et al. | Sep 1993 | A |
5254109 | Smith et al. | Oct 1993 | A |
5290273 | Tan | Mar 1994 | A |
5368581 | Smith et al. | Nov 1994 | A |
5387215 | Fisher | Feb 1995 | A |
5391151 | Wilmot | Feb 1995 | A |
5417674 | Smith et al. | May 1995 | A |
5419772 | Teitz et al. | May 1995 | A |
5423803 | Tankovich et al. | Jun 1995 | A |
5437372 | Per-Lee | Aug 1995 | A |
5441490 | Svedman | Aug 1995 | A |
5460620 | Smith et al. | Oct 1995 | A |
5470323 | Smith et al. | Nov 1995 | A |
5484427 | Gibbons | Jan 1996 | A |
5490736 | Haber et al. | Feb 1996 | A |
5512044 | Duer | Apr 1996 | A |
5562642 | Smith et al. | Oct 1996 | A |
5562643 | Johnson | Oct 1996 | A |
5611687 | Wagner | Mar 1997 | A |
5612797 | Clarke | Mar 1997 | A |
5618275 | Bock | Apr 1997 | A |
5626631 | Eckhouse | May 1997 | A |
5658323 | Miller | Aug 1997 | A |
5658583 | Zhang et al. | Aug 1997 | A |
5674235 | Parisi | Oct 1997 | A |
5676643 | Cann et al. | Oct 1997 | A |
5676648 | Henley | Oct 1997 | A |
5683971 | Rose et al. | Nov 1997 | A |
5697920 | Gibbons | Dec 1997 | A |
5707383 | Bays | Jan 1998 | A |
5713785 | Nishio | Feb 1998 | A |
5735833 | Olson | Apr 1998 | A |
5755751 | Eckhouse | May 1998 | A |
5759185 | Grinberg | Jun 1998 | A |
5762640 | Kajiwara et al. | Jun 1998 | A |
5779519 | Oliver | Jul 1998 | A |
5800446 | Banuchi | Sep 1998 | A |
5807353 | Schmitz | Sep 1998 | A |
5810842 | Di Fiore et al. | Sep 1998 | A |
5813416 | Rudolph | Sep 1998 | A |
5817050 | Klein | Oct 1998 | A |
5817089 | Tankovich et al. | Oct 1998 | A |
5834510 | Yu et al. | Nov 1998 | A |
5846215 | Zygmont | Dec 1998 | A |
5848998 | Marasco, Jr. | Dec 1998 | A |
5857995 | Thomas et al. | Jan 1999 | A |
5861142 | Schick | Jan 1999 | A |
5873881 | McEwen et al. | Feb 1999 | A |
5879323 | Henley | Mar 1999 | A |
5879376 | Miller | Mar 1999 | A |
5882201 | Salem | Mar 1999 | A |
5885260 | Mehl, Sr. et al. | Mar 1999 | A |
5908401 | Henley | Jun 1999 | A |
5911223 | Weaver et al. | Jun 1999 | A |
5919152 | Zygmont | Jul 1999 | A |
5919479 | Zhang et al. | Jul 1999 | A |
5954730 | Bernabei | Sep 1999 | A |
5971999 | Naldoni | Oct 1999 | A |
5980555 | Barbut et al. | Nov 1999 | A |
6019749 | Fields et al. | Feb 2000 | A |
6023639 | Hakky et al. | Feb 2000 | A |
6024733 | Eggers et al. | Feb 2000 | A |
6027402 | Oliver | Feb 2000 | A |
6027495 | Miller | Feb 2000 | A |
6032071 | Binder | Feb 2000 | A |
6036684 | Tankovich et al. | Mar 2000 | A |
6039745 | Di Fiore et al. | Mar 2000 | A |
6042552 | Cornier | Mar 2000 | A |
D425241 | Nishizawa et al. | May 2000 | S |
6074382 | Asah et al. | Jun 2000 | A |
6080165 | DeJacma | Jun 2000 | A |
6080166 | McEwen et al. | Jun 2000 | A |
D428142 | Stromblad | Jul 2000 | S |
6090085 | Mehl, Sr. et al. | Jul 2000 | A |
6093021 | Rainey | Jul 2000 | A |
6113559 | Klopotek | Sep 2000 | A |
6120512 | Bernabei | Sep 2000 | A |
6129701 | Cimino | Oct 2000 | A |
6136008 | Becker et al. | Oct 2000 | A |
6139553 | Dotan | Oct 2000 | A |
6139554 | Karkar et al. | Oct 2000 | A |
6142155 | Rudolph | Nov 2000 | A |
6149634 | Bernabei | Nov 2000 | A |
6149644 | Xie | Nov 2000 | A |
6159226 | Kim | Dec 2000 | A |
6162218 | Elbrecht et al. | Dec 2000 | A |
6162232 | Shadduck | Dec 2000 | A |
6165059 | Park et al. | Dec 2000 | A |
6174325 | Eckhouse | Jan 2001 | B1 |
6176198 | Kao et al. | Jan 2001 | B1 |
6183451 | Mehl, Sr. et al. | Feb 2001 | B1 |
6183483 | Chang | Feb 2001 | B1 |
6190376 | Asah et al. | Feb 2001 | B1 |
6193589 | Khalaj | Feb 2001 | B1 |
6196982 | Ball | Mar 2001 | B1 |
6231593 | Meserol | May 2001 | B1 |
6235039 | Parkin et al. | May 2001 | B1 |
6238275 | Metcalf et al. | May 2001 | B1 |
6241739 | Waldron | Jun 2001 | B1 |
6245347 | Zhang et al. | Jun 2001 | B1 |
6264666 | Coleman et al. | Jul 2001 | B1 |
6269271 | Bernabei | Jul 2001 | B1 |
6277116 | Utely et al. | Aug 2001 | B1 |
6277128 | Muldner | Aug 2001 | B1 |
6280438 | Eckhouse et al. | Aug 2001 | B1 |
6283978 | Cheski et al. | Sep 2001 | B1 |
6284266 | Zhang et al. | Sep 2001 | B1 |
6299620 | Shadduck | Oct 2001 | B1 |
6306119 | Weber et al. | Oct 2001 | B1 |
6306147 | Bernabei et al. | Oct 2001 | B1 |
6322548 | Payne et al. | Nov 2001 | B1 |
6322568 | Bernabei et al. | Nov 2001 | B1 |
6325381 | von Engelbrechten | Dec 2001 | B1 |
6325769 | Klopotek | Dec 2001 | B1 |
6332886 | Green et al. | Dec 2001 | B1 |
6334074 | Spertell | Dec 2001 | B1 |
6355054 | Neuberger | Mar 2002 | B1 |
6368333 | Bernabei et al. | Apr 2002 | B2 |
6383177 | Balle-Petersen et al. | May 2002 | B1 |
6387089 | Kreindel et al. | May 2002 | B1 |
6387103 | Shadduck | May 2002 | B2 |
6401289 | Herbert | Jun 2002 | B1 |
6409736 | Bernabei | Jun 2002 | B1 |
6410599 | Johnson | Jun 2002 | B1 |
RE37796 | Henley | Jul 2002 | E |
6414032 | Johnson | Jul 2002 | B1 |
6420431 | Johnson | Jul 2002 | B1 |
6423078 | Bays et al. | Jul 2002 | B1 |
6423750 | Johnson | Jul 2002 | B1 |
6432113 | Parkin et al. | Aug 2002 | B1 |
6432114 | Rosso | Aug 2002 | B1 |
6458109 | Henley et al. | Oct 2002 | B1 |
6471712 | Burres | Oct 2002 | B2 |
6477410 | Henley et al. | Nov 2002 | B1 |
6482212 | Bernabei et al. | Nov 2002 | B1 |
6488646 | Zygmont | Dec 2002 | B1 |
6494856 | Zygmont | Dec 2002 | B1 |
6500183 | Waldron | Dec 2002 | B1 |
6503256 | Parkin et al. | Jan 2003 | B2 |
6508813 | Altshuler | Jan 2003 | B1 |
6511486 | Mercier et al. | Jan 2003 | B2 |
6514243 | Eckhouse et al. | Feb 2003 | B1 |
6514262 | Di Fiore et al. | Feb 2003 | B1 |
6514278 | Hibst et al. | Feb 2003 | B1 |
6518538 | Bernabei | Feb 2003 | B2 |
6520931 | Suh | Feb 2003 | B2 |
D472136 | Hermann | Mar 2003 | S |
6527716 | Eppstein | Mar 2003 | B1 |
6527783 | Ignon | Mar 2003 | B1 |
6533776 | Asah et al. | Mar 2003 | B2 |
6535761 | Bernabei | Mar 2003 | B2 |
6537242 | Palmer | Mar 2003 | B1 |
6540757 | Hruska et al. | Apr 2003 | B1 |
6546281 | Zhang et al. | Apr 2003 | B1 |
6562013 | Marasco, Jr. | May 2003 | B1 |
6562050 | Owen | May 2003 | B1 |
6564093 | Ostrow et al. | May 2003 | B1 |
6565535 | Zaias et al. | May 2003 | B2 |
6569157 | Shain et al. | May 2003 | B1 |
6582442 | Simon et al. | Jun 2003 | B2 |
6587730 | Bernabei | Jul 2003 | B2 |
6589218 | Garcia | Jul 2003 | B2 |
6592595 | Mallett et al. | Jul 2003 | B1 |
6595934 | Hissong et al. | Jul 2003 | B1 |
6611706 | Avrahami et al. | Aug 2003 | B2 |
6626445 | Murphy et al. | Sep 2003 | B2 |
6629927 | Mesaros et al. | Oct 2003 | B1 |
6629971 | McDaniel | Oct 2003 | B2 |
6629974 | Penny et al. | Oct 2003 | B2 |
6629983 | Ignon | Oct 2003 | B1 |
6635035 | Marasco et al. | Oct 2003 | B1 |
6641591 | Shadduck | Nov 2003 | B1 |
6645184 | Zelickson et al. | Nov 2003 | B1 |
6652888 | Rhoades | Nov 2003 | B2 |
6666874 | Heitzmann et al. | Dec 2003 | B2 |
6673081 | Tavger et al. | Jan 2004 | B1 |
6673082 | Mallett et al. | Jan 2004 | B2 |
D486915 | Warschewske et al. | Feb 2004 | S |
6685853 | Angelopoulous et al. | Feb 2004 | B1 |
6687537 | Bernabei | Feb 2004 | B2 |
6689380 | Marchitto et al. | Feb 2004 | B1 |
6695853 | Karasiuk | Feb 2004 | B2 |
6699237 | Weber et al. | Mar 2004 | B2 |
6712805 | Weimann | Mar 2004 | B2 |
6726673 | Zhang et al. | Apr 2004 | B1 |
D490561 | Angeletta | May 2004 | S |
6735470 | Henley et al. | May 2004 | B2 |
6743211 | Prausnitz et al. | Jun 2004 | B1 |
6743215 | Bernabei | Jun 2004 | B2 |
6764493 | Weber et al. | Jul 2004 | B1 |
6780426 | Zhang et al. | Aug 2004 | B2 |
D496101 | Davison | Sep 2004 | S |
6800083 | Hiblar et al. | Oct 2004 | B2 |
6800849 | Staats | Oct 2004 | B2 |
D499207 | Angeletta | Nov 2004 | S |
D499841 | Angeletta | Dec 2004 | S |
D502288 | Longoria | Feb 2005 | S |
D502289 | Longoria | Feb 2005 | S |
D502569 | Longoria | Mar 2005 | S |
6869611 | Kligman et al. | Mar 2005 | B1 |
6878144 | Altshuler et al. | Apr 2005 | B2 |
6887260 | McDaniel | May 2005 | B1 |
6905487 | Zimmerman | Jun 2005 | B2 |
6911031 | Muldner | Jun 2005 | B2 |
6926681 | Ramey et al. | Aug 2005 | B1 |
6938805 | Brincat | Sep 2005 | B2 |
6942649 | Ignon et al. | Sep 2005 | B2 |
6960206 | Keane | Nov 2005 | B2 |
6980448 | Foss et al. | Dec 2005 | B2 |
7001355 | Nunomura et al. | Feb 2006 | B2 |
7004933 | McDaniel | Feb 2006 | B2 |
D517699 | Lansohn | Mar 2006 | S |
7031805 | Lee et al. | Apr 2006 | B2 |
7044938 | La Bianco et al. | May 2006 | B2 |
7051907 | Brincat | May 2006 | B2 |
7052503 | Bernabei | May 2006 | B2 |
D522360 | Caserta et al. | Jun 2006 | S |
7062317 | Avrahami et al. | Jun 2006 | B2 |
7069073 | Henley et al. | Jun 2006 | B2 |
7070488 | Suissa et al. | Jul 2006 | B2 |
7083580 | Bernabei | Aug 2006 | B2 |
7087036 | Busby et al. | Aug 2006 | B2 |
7087063 | Carson et al. | Aug 2006 | B2 |
7094252 | Koop | Aug 2006 | B2 |
7108689 | Eckhouse et al. | Sep 2006 | B2 |
7115275 | Clarot et al. | Oct 2006 | B2 |
7118563 | Weckwerth et al. | Oct 2006 | B2 |
7122029 | Koop et al. | Oct 2006 | B2 |
7135011 | Powers et al. | Nov 2006 | B2 |
D533962 | Angeletta | Dec 2006 | S |
7153311 | Chung | Dec 2006 | B2 |
7166086 | Haider et al. | Jan 2007 | B2 |
D536481 | Angeletta | Feb 2007 | S |
7172572 | Diamond et al. | Feb 2007 | B2 |
7189230 | Knowlton | Mar 2007 | B2 |
7197359 | Tokudome et al. | Mar 2007 | B1 |
7198623 | Fischer et al. | Apr 2007 | B2 |
7201765 | McDaniel | Apr 2007 | B2 |
D545207 | De Baschmakoff | Jun 2007 | S |
7232431 | Weimann | Jun 2007 | B1 |
7232444 | Chang | Jun 2007 | B2 |
7241208 | Suissa et al. | Jul 2007 | B2 |
7250045 | Island et al. | Jul 2007 | B2 |
D548341 | Ohta et al. | Aug 2007 | S |
D548843 | Kertz | Aug 2007 | S |
D553005 | Py et al. | Oct 2007 | S |
7276051 | Henley et al. | Oct 2007 | B1 |
7293930 | Chuang | Nov 2007 | B2 |
D557611 | Ingemarsson | Dec 2007 | S |
7314326 | Rosenberg | Jan 2008 | B2 |
7316657 | Kleinhenz et al. | Jan 2008 | B2 |
7316671 | Lastovich et al. | Jan 2008 | B2 |
7318828 | Revivo | Jan 2008 | B1 |
7320691 | Pilcher et al. | Jan 2008 | B2 |
7320801 | Kelly | Jan 2008 | B2 |
7326199 | MacFarland et al. | Feb 2008 | B2 |
7329252 | Yamazaki et al. | Feb 2008 | B1 |
7354423 | Zelickson et al. | Apr 2008 | B2 |
7364565 | Freeman | Apr 2008 | B2 |
D568473 | Ashiwa et al. | May 2008 | S |
7367981 | Bernaz | May 2008 | B2 |
7384405 | Rhoades | Jun 2008 | B2 |
7422567 | Lastovich et al. | Sep 2008 | B2 |
7427273 | Mitsui | Sep 2008 | B2 |
7440798 | Redding, Jr. | Oct 2008 | B2 |
7458944 | Liste et al. | Dec 2008 | B2 |
D584151 | Murphy | Jan 2009 | S |
7476205 | Erdmann | Jan 2009 | B2 |
7477938 | Sun et al. | Jan 2009 | B2 |
7482314 | Grimes et al. | Jan 2009 | B2 |
7485125 | Sjostrom | Feb 2009 | B2 |
7489989 | Sukhanov et al. | Feb 2009 | B2 |
7494503 | McDaniel | Feb 2009 | B2 |
7507228 | Sun et al. | Mar 2009 | B2 |
7572238 | Rhoades | Aug 2009 | B2 |
7582067 | Van Acker | Sep 2009 | B2 |
7597900 | Zimmer et al. | Oct 2009 | B2 |
7597901 | Clarot et al. | Oct 2009 | B2 |
7607972 | Groman | Oct 2009 | B2 |
7658742 | Karasiuk | Feb 2010 | B2 |
7678120 | Shadduck | Mar 2010 | B2 |
7730979 | Kahrig | Jun 2010 | B2 |
7731570 | Groman | Jun 2010 | B2 |
7740651 | Barak et al. | Jun 2010 | B2 |
7744582 | Sadowski et al. | Jun 2010 | B2 |
7749260 | Da Silva et al. | Jul 2010 | B2 |
7758537 | Brunell et al. | Jul 2010 | B1 |
7771374 | Slatkine | Aug 2010 | B2 |
7780652 | MacFarland et al. | Aug 2010 | B2 |
7789886 | Shadduck | Sep 2010 | B2 |
D625198 | Hall | Oct 2010 | S |
7814915 | Davenport et al. | Oct 2010 | B2 |
7837695 | Hart et al. | Nov 2010 | B2 |
7857806 | Karpowicz et al. | Dec 2010 | B2 |
7862564 | Goble | Jan 2011 | B2 |
7901373 | Tavger | Mar 2011 | B2 |
7927188 | Groman | Apr 2011 | B2 |
7951156 | Karasiuk | May 2011 | B2 |
D639164 | Walsh | Jun 2011 | S |
7981111 | Grove et al. | Jul 2011 | B2 |
7981112 | Neev | Jul 2011 | B1 |
7993333 | Oral et al. | Aug 2011 | B2 |
8025669 | David et al. | Sep 2011 | B1 |
RE42960 | Waldron | Nov 2011 | E |
8048064 | Hwang et al. | Nov 2011 | B2 |
8048089 | Ignon et al. | Nov 2011 | B2 |
8066716 | Shadduck | Nov 2011 | B2 |
8088085 | Thiebaut et al. | Jan 2012 | B2 |
8105295 | Blott et al. | Jan 2012 | B2 |
8128638 | Karasiuk et al. | Mar 2012 | B2 |
8135475 | Kreindel et al. | Mar 2012 | B2 |
8182473 | Altshuler et al. | May 2012 | B2 |
D664254 | Yokoyama et al. | Jul 2012 | S |
8221437 | Waldron et al. | Jul 2012 | B2 |
8226663 | Remsburg et al. | Jul 2012 | B2 |
8231292 | Rabe et al. | Jul 2012 | B2 |
8236008 | Boone, III et al. | Aug 2012 | B2 |
8236036 | Frost | Aug 2012 | B1 |
8241094 | Groman | Aug 2012 | B2 |
8273080 | Mehta | Sep 2012 | B2 |
8276592 | Davenport et al. | Oct 2012 | B2 |
8277287 | Hart | Oct 2012 | B2 |
8282630 | Neev | Oct 2012 | B2 |
8313480 | Neev | Nov 2012 | B2 |
8317781 | Owens et al. | Nov 2012 | B2 |
8323253 | Hantash et al. | Dec 2012 | B2 |
8337513 | Shadduck | Dec 2012 | B2 |
8343116 | Ignon et al. | Jan 2013 | B2 |
8360826 | Groman | Jan 2013 | B2 |
D676764 | Moore et al. | Feb 2013 | S |
D678783 | Wilcox et al. | Mar 2013 | S |
8398621 | Beerwerth et al. | Mar 2013 | B2 |
D680437 | Bartolo et al. | Apr 2013 | S |
8430104 | Hennings et al. | Apr 2013 | B2 |
8435234 | Chan et al. | May 2013 | B2 |
8475507 | Dewey et al. | Jul 2013 | B2 |
8478396 | Tsao et al. | Jul 2013 | B2 |
8480721 | Owens et al. | Jul 2013 | B2 |
8496654 | Adanny et al. | Jul 2013 | B2 |
8496695 | Kang et al. | Jul 2013 | B2 |
8535299 | Giovannoli | Sep 2013 | B2 |
8545419 | Kim | Oct 2013 | B2 |
8545489 | Giovannoli | Oct 2013 | B2 |
8551104 | Weckwerth et al. | Oct 2013 | B2 |
8562626 | Sabir et al. | Oct 2013 | B2 |
8573874 | Neuner | Nov 2013 | B2 |
8579916 | Cheney | Nov 2013 | B2 |
8597284 | Castro | Dec 2013 | B2 |
D697404 | Johnson et al. | Jan 2014 | S |
8632378 | Groman | Jan 2014 | B2 |
D699367 | Lee et al. | Feb 2014 | S |
8656931 | Davenport et al. | Feb 2014 | B2 |
8668552 | Groman | Mar 2014 | B2 |
8679039 | Tieu et al. | Mar 2014 | B2 |
8700176 | Azar et al. | Apr 2014 | B2 |
8702691 | Weber et al. | Apr 2014 | B2 |
8702771 | Frost | Apr 2014 | B1 |
8721662 | Karasiuk | May 2014 | B2 |
8728064 | Schomacker et al. | May 2014 | B2 |
8740917 | Pilcher et al. | Jun 2014 | B2 |
D709617 | Iliesco de Grimaldi et al. | Jul 2014 | S |
8814836 | Ignon et al. | Aug 2014 | B2 |
8818500 | Duquet et al. | Aug 2014 | B2 |
8821940 | Harris et al. | Sep 2014 | B2 |
8834933 | Harris et al. | Sep 2014 | B2 |
8858570 | Chang | Oct 2014 | B2 |
8939669 | Le et al. | Jan 2015 | B2 |
D722172 | Amemiya et al. | Feb 2015 | S |
8945104 | Boone, III et al. | Feb 2015 | B2 |
8945109 | Mehta | Feb 2015 | B2 |
8974442 | Boss, Jr. | Mar 2015 | B1 |
9017391 | McDaniel | Apr 2015 | B2 |
9017392 | Owens et al. | Apr 2015 | B2 |
9044582 | Chang et al. | Jun 2015 | B2 |
9050133 | Boone, III et al. | Jun 2015 | B1 |
9050156 | Groman | Jun 2015 | B2 |
9056193 | Ignon et al. | Jun 2015 | B2 |
D734154 | Johnson et al. | Jul 2015 | S |
9072521 | Levi et al. | Jul 2015 | B2 |
9072533 | Liu et al. | Jul 2015 | B2 |
9072892 | Owens et al. | Jul 2015 | B2 |
9084587 | Eckhouse et al. | Jul 2015 | B2 |
9149322 | Knowlton | Oct 2015 | B2 |
D743269 | Pape | Nov 2015 | S |
D743558 | Kim et al. | Nov 2015 | S |
9186490 | Chang et al. | Nov 2015 | B2 |
9227044 | Bansal et al. | Jan 2016 | B2 |
9227082 | McDaniel | Jan 2016 | B2 |
9233207 | Polyakov et al. | Jan 2016 | B2 |
9271755 | Luzon et al. | Mar 2016 | B2 |
9278230 | Levin et al. | Mar 2016 | B2 |
9283037 | Bragagna et al. | Mar 2016 | B2 |
9314302 | Dougal | Apr 2016 | B2 |
9351792 | Manstein et al. | May 2016 | B2 |
9351794 | Suckewer et al. | May 2016 | B2 |
9375281 | Moench et al. | Jun 2016 | B2 |
9421260 | Harris et al. | Aug 2016 | B2 |
9421261 | Harris et al. | Aug 2016 | B2 |
D765512 | Joulia | Sep 2016 | S |
9439964 | Harris et al. | Sep 2016 | B2 |
9440093 | Homer | Sep 2016 | B2 |
9452013 | Manstein | Sep 2016 | B2 |
9468464 | Shadduck | Oct 2016 | B2 |
9474886 | Ignon et al. | Oct 2016 | B2 |
D772481 | Paquet | Nov 2016 | S |
9480836 | Na | Nov 2016 | B2 |
9486615 | Ignon et al. | Nov 2016 | B2 |
9498610 | Ignon et al. | Nov 2016 | B2 |
9517085 | Karasiuk | Dec 2016 | B2 |
9522287 | Owens et al. | Dec 2016 | B2 |
9550052 | Ignon | Jan 2017 | B2 |
9566088 | Ignon et al. | Feb 2017 | B2 |
9566454 | Barthe et al. | Feb 2017 | B2 |
9572880 | Harris et al. | Feb 2017 | B2 |
9597527 | Buchholz et al. | Mar 2017 | B2 |
D782881 | Seiders et al. | Apr 2017 | S |
D787054 | Rini et al. | May 2017 | S |
9636521 | Isserow et al. | May 2017 | B2 |
9636522 | Oversluizen et al. | May 2017 | B2 |
9642997 | Ignon et al. | May 2017 | B2 |
9662482 | Ignon et al. | May 2017 | B2 |
9669233 | Quisenberry et al. | Jun 2017 | B2 |
9675817 | Isserow et al. | Jun 2017 | B2 |
9694199 | Duquet et al. | Jul 2017 | B2 |
9700684 | Vlodaver et al. | Jul 2017 | B2 |
9731053 | Alai | Aug 2017 | B2 |
9744315 | Levi | Aug 2017 | B1 |
9775645 | Boone, III | Oct 2017 | B2 |
9775646 | Shadduck | Oct 2017 | B2 |
9775976 | Grez | Oct 2017 | B2 |
9814485 | Pratt et al. | Nov 2017 | B2 |
9814647 | Ajiki | Nov 2017 | B2 |
9814868 | Ignon et al. | Nov 2017 | B2 |
9814906 | McDaniel | Nov 2017 | B2 |
9833261 | Boone, III et al. | Dec 2017 | B2 |
9861442 | Tankovich et al. | Jan 2018 | B2 |
D811225 | Newson | Feb 2018 | S |
D811381 | Morohoshi et al. | Feb 2018 | S |
9918727 | Boone, III et al. | Mar 2018 | B1 |
9949552 | Rabe et al. | Apr 2018 | B2 |
9950147 | Mehta | Apr 2018 | B2 |
9955769 | Rabe et al. | May 2018 | B2 |
9962220 | Domankevitz | May 2018 | B2 |
9968800 | Anderson et al. | May 2018 | B2 |
10004919 | Lemmens et al. | Jun 2018 | B2 |
D822845 | Shimobayashi et al. | Jul 2018 | S |
10010445 | Isserow et al. | Jul 2018 | B2 |
10022289 | Ajiki et al. | Jul 2018 | B2 |
10035007 | Ignon et al. | Jul 2018 | B2 |
D825763 | Lim et al. | Aug 2018 | S |
10052467 | Bansal et al. | Aug 2018 | B2 |
D829333 | Shin et al. | Sep 2018 | S |
10076354 | Knowlton | Sep 2018 | B2 |
10076646 | Casasanta, III et al. | Sep 2018 | B2 |
10080581 | Knowlton | Sep 2018 | B2 |
D829921 | Xiong | Oct 2018 | S |
10092478 | Amit | Oct 2018 | B1 |
10105191 | Blanco et al. | Oct 2018 | B2 |
D833283 | Rock | Nov 2018 | S |
10130390 | Hart et al. | Nov 2018 | B1 |
10130827 | Buchholz et al. | Nov 2018 | B2 |
D836781 | Meurer et al. | Dec 2018 | S |
10149969 | Grez et al. | Dec 2018 | B2 |
10149984 | Modi et al. | Dec 2018 | B2 |
10172644 | Ignon et al. | Jan 2019 | B2 |
10179229 | Ignon et al. | Jan 2019 | B2 |
10183183 | Burdette | Jan 2019 | B2 |
10188193 | Rabe et al. | Jan 2019 | B2 |
10206743 | Tankovich et al. | Feb 2019 | B2 |
10207034 | Collins | Feb 2019 | B2 |
10220122 | Clark, III et al. | Mar 2019 | B2 |
10238812 | Ignon | Mar 2019 | B2 |
10238849 | Britva et al. | Mar 2019 | B2 |
10251675 | Ignon et al. | Apr 2019 | B2 |
10252044 | Bock | Apr 2019 | B2 |
10271900 | Marchitto et al. | Apr 2019 | B2 |
10272258 | Quisenberry et al. | Apr 2019 | B2 |
D851759 | Jones et al. | Jun 2019 | S |
10307330 | Sedic | Jun 2019 | B1 |
10308378 | Goodwin et al. | Jun 2019 | B2 |
10314378 | Rabe et al. | Jun 2019 | B2 |
10321948 | Knowlton | Jun 2019 | B2 |
10322233 | Hanson et al. | Jun 2019 | B2 |
10328277 | Modi et al. | Jun 2019 | B2 |
D852962 | Chang | Jul 2019 | S |
10335191 | Knowlton | Jul 2019 | B2 |
10357641 | Ignon et al. | Jul 2019 | B2 |
10357642 | Ignon et al. | Jul 2019 | B2 |
10334933 | Rosario et al. | Aug 2019 | B2 |
10369073 | Rosario et al. | Aug 2019 | B2 |
10413359 | Felsenstein et al. | Sep 2019 | B2 |
D861913 | Stamm et al. | Oct 2019 | S |
10456197 | Felsenstein et al. | Oct 2019 | B2 |
10456321 | Shadduck | Oct 2019 | B2 |
10456567 | Streeter | Oct 2019 | B2 |
D867587 | Holtz | Nov 2019 | S |
10463429 | Deem et al. | Nov 2019 | B2 |
10471274 | Liu et al. | Nov 2019 | B2 |
10485983 | Boone, III et al. | Nov 2019 | B1 |
D868981 | Salamon et al. | Dec 2019 | S |
D873430 | Accolla | Jan 2020 | S |
D873481 | Larkin | Jan 2020 | S |
10524835 | Shadduck et al. | Jan 2020 | B2 |
10537304 | Barthe et al. | Jan 2020 | B2 |
10537640 | Harris et al. | Jan 2020 | B2 |
10556096 | Ignon et al. | Feb 2020 | B2 |
10556097 | Ignon et al. | Feb 2020 | B2 |
10583037 | Isserow et al. | Mar 2020 | B2 |
D886370 | Soutelo Gomes | Jun 2020 | S |
D886372 | Weinrich | Jun 2020 | S |
D887571 | Liu | Jun 2020 | S |
10667985 | Decaux et al. | Jun 2020 | B2 |
10675481 | Tankovich | Jun 2020 | B1 |
10688290 | Yuval | Jun 2020 | B1 |
10702328 | Slatkine et al. | Jul 2020 | B2 |
10716924 | Knowlton | Jul 2020 | B2 |
D893024 | Whiteside | Aug 2020 | S |
10736653 | Knowlton | Aug 2020 | B2 |
10737080 | Patterson | Aug 2020 | B2 |
10758261 | Richardson | Sep 2020 | B2 |
10772658 | Knowlton | Sep 2020 | B2 |
10792382 | Rafko | Oct 2020 | B2 |
10799285 | Mulholland | Oct 2020 | B2 |
10799430 | Danto | Oct 2020 | B2 |
10813694 | Johnson et al. | Oct 2020 | B2 |
10835287 | Shadduck et al. | Nov 2020 | B2 |
10835726 | Redding, Jr. | Nov 2020 | B2 |
D903889 | Luo et al. | Dec 2020 | S |
10850095 | Ebbers et al. | Dec 2020 | B2 |
10856900 | Knowlton | Dec 2020 | B2 |
10860026 | Nguyen et al. | Dec 2020 | B2 |
10874579 | Rembert | Dec 2020 | B1 |
D908282 | Kim | Jan 2021 | S |
10893907 | Kim | Jan 2021 | B2 |
10912428 | Daffer | Feb 2021 | B2 |
10918190 | Laudati | Feb 2021 | B2 |
10946191 | Cazares Delgadillo | Mar 2021 | B2 |
10952811 | Blanco et al. | Mar 2021 | B2 |
10952907 | Carver | Mar 2021 | B1 |
D917290 | Bravman et al. | Apr 2021 | S |
10980592 | Horton et al. | Apr 2021 | B2 |
10993743 | Ignon et al. | May 2021 | B2 |
11020577 | Ignon et al. | Jun 2021 | B2 |
11045661 | Oversluizen et al. | Jun 2021 | B2 |
D927008 | Rappaport | Aug 2021 | S |
D928977 | Dijkstra | Aug 2021 | S |
11083515 | Slatkine et al. | Aug 2021 | B2 |
11123039 | Barthe et al. | Sep 2021 | B2 |
11141761 | Connelly et al. | Oct 2021 | B2 |
11154723 | Lee | Oct 2021 | B2 |
11172978 | Wootten et al. | Nov 2021 | B2 |
11202657 | Ignon et al. | Dec 2021 | B2 |
11213321 | Ignon et al. | Jan 2022 | B2 |
11224728 | Ignon et al. | Jan 2022 | B2 |
11241357 | Ignon et al. | Feb 2022 | B2 |
11247039 | Schwarz | Feb 2022 | B2 |
11278101 | Jeannin et al. | Mar 2022 | B2 |
11291474 | Nicolas et al. | Apr 2022 | B2 |
11291498 | Slatkine et al. | Apr 2022 | B2 |
11311721 | Ebbers et al. | Apr 2022 | B2 |
11337745 | Kim | May 2022 | B2 |
11337755 | Hancock et al. | May 2022 | B2 |
11351063 | Locke et al. | Jun 2022 | B2 |
11419678 | Deem et al. | Aug 2022 | B2 |
D964581 | Guo | Sep 2022 | S |
11446477 | Ignon et al. | Sep 2022 | B2 |
11452852 | Quan et al. | Sep 2022 | B2 |
11452883 | Marchese et al. | Sep 2022 | B1 |
11497553 | Reinhard et al. | Nov 2022 | B2 |
11504148 | Friend | Nov 2022 | B2 |
11517350 | Ignon et al. | Dec 2022 | B2 |
11540882 | Masotti et al. | Jan 2023 | B2 |
11547840 | Ignon et al. | Jan 2023 | B2 |
D979782 | Sung et al. | Feb 2023 | S |
11590345 | Danitz et al. | Feb 2023 | B2 |
11602629 | Schwarz et al. | Mar 2023 | B2 |
11612726 | Ignon et al. | Mar 2023 | B2 |
D994134 | Lim | Aug 2023 | S |
11717326 | Ignon et al. | Aug 2023 | B2 |
D998143 | Nagao et al. | Sep 2023 | S |
11744999 | Ignon et al. | Sep 2023 | B2 |
11806495 | Ignon et al. | Nov 2023 | B2 |
D1011541 | Yu | Jan 2024 | S |
11865287 | Ignon et al. | Jan 2024 | B2 |
11883621 | Ignon et al. | Jan 2024 | B2 |
11903615 | Ignon et al. | Feb 2024 | B2 |
D1016615 | Rozporka et al. | Mar 2024 | S |
11925780 | Ignon et al. | Mar 2024 | B2 |
20010023351 | Eilers | Sep 2001 | A1 |
20010037118 | Shadduck | Nov 2001 | A1 |
20010049511 | Coleman | Dec 2001 | A1 |
20020016601 | Shadduck | Feb 2002 | A1 |
20020040199 | Klopotek | Apr 2002 | A1 |
20020041891 | Cheski | Apr 2002 | A1 |
20020058952 | Weber et al. | May 2002 | A1 |
20020099356 | Unger et al. | Jul 2002 | A1 |
20020107527 | Burres | Aug 2002 | A1 |
20020128663 | Mercier et al. | Sep 2002 | A1 |
20020133110 | Citow | Sep 2002 | A1 |
20020133176 | Parkin et al. | Sep 2002 | A1 |
20020151826 | Ramey et al. | Oct 2002 | A1 |
20020151908 | Mallett, Sr. et al. | Oct 2002 | A1 |
20020162863 | Brincat | Nov 2002 | A1 |
20020188261 | Hruska | Dec 2002 | A1 |
20020198488 | Yao | Dec 2002 | A1 |
20030012415 | Cossel | Jan 2003 | A1 |
20030018252 | Duchon | Jan 2003 | A1 |
20030060834 | Muldner | Mar 2003 | A1 |
20030093040 | Mikszta et al. | May 2003 | A1 |
20030093089 | Greenberg | May 2003 | A1 |
20030097139 | Karasiuk | May 2003 | A1 |
20030135388 | Martucci et al. | Jul 2003 | A1 |
20030167032 | Ignon et al. | Sep 2003 | A1 |
20030187462 | Chang | Oct 2003 | A1 |
20030208159 | Ignon et al. | Nov 2003 | A1 |
20030212127 | Glassman et al. | Nov 2003 | A1 |
20030212415 | Karasiuk | Nov 2003 | A1 |
20040005349 | Neev | Jan 2004 | A1 |
20040010222 | Nunomura et al. | Jan 2004 | A1 |
20040010269 | Grimes et al. | Jan 2004 | A1 |
20040015139 | La Bianco | Jan 2004 | A1 |
20040051368 | Caputo et al. | Mar 2004 | A1 |
20040087972 | Mulholland et al. | May 2004 | A1 |
20040092895 | Harmon | May 2004 | A1 |
20040092959 | Bernaz | May 2004 | A1 |
20040097967 | Ignon | May 2004 | A1 |
20040122447 | Harmon et al. | Jun 2004 | A1 |
20040127914 | Chung | Jul 2004 | A1 |
20040138680 | Twitchell et al. | Jul 2004 | A1 |
20040162565 | Carson et al. | Aug 2004 | A1 |
20040166172 | Rosati et al. | Aug 2004 | A1 |
20040176823 | Island et al. | Sep 2004 | A1 |
20040210167 | Webster | Oct 2004 | A1 |
20040210280 | Liedtke | Oct 2004 | A1 |
20040219179 | McDaniel | Nov 2004 | A1 |
20040229295 | Marchitto et al. | Nov 2004 | A1 |
20040236291 | Zelickson et al. | Nov 2004 | A1 |
20040236375 | Redding, Jr. | Nov 2004 | A1 |
20040243149 | Lee, Jr. | Dec 2004 | A1 |
20040254587 | Park | Dec 2004 | A1 |
20040267285 | Chang | Dec 2004 | A1 |
20050015077 | Kuklin et al. | Jan 2005 | A1 |
20050037034 | Rhoades | Feb 2005 | A1 |
20050038377 | Redding, Jr. | Feb 2005 | A1 |
20050038448 | Chung | Feb 2005 | A1 |
20050059940 | Weber et al. | Mar 2005 | A1 |
20050065461 | Redding, Jr. | Mar 2005 | A1 |
20050070977 | Molina | Mar 2005 | A1 |
20050075599 | Redding, Jr. | Apr 2005 | A1 |
20050080465 | Zelickson et al. | Apr 2005 | A1 |
20050084509 | Bernstein | Apr 2005 | A1 |
20050148958 | Rucinski | Jul 2005 | A1 |
20050154333 | Mulholland et al. | Jul 2005 | A1 |
20050203111 | David | Sep 2005 | A1 |
20050203593 | Shanks et al. | Sep 2005 | A1 |
20050209611 | Greenberg | Sep 2005 | A1 |
20050245180 | Suissa et al. | Nov 2005 | A1 |
20050283176 | Law | Dec 2005 | A1 |
20060002960 | Zoeteweij et al. | Jan 2006 | A1 |
20060015059 | Redding, Jr. | Jan 2006 | A1 |
20060058714 | Rhoades | Mar 2006 | A1 |
20060100567 | Marchitto et al. | May 2006 | A1 |
20060116674 | Goble et al. | Jun 2006 | A1 |
20060161178 | Lee | Jul 2006 | A1 |
20060184071 | Klopotek | Aug 2006 | A1 |
20060189964 | Anderson | Aug 2006 | A1 |
20060191562 | Numomura | Aug 2006 | A1 |
20060200099 | La Bianco et al. | Sep 2006 | A1 |
20060200213 | McDaniel | Sep 2006 | A1 |
20060212025 | McDaniel | Sep 2006 | A1 |
20060212029 | Villacampa et al. | Sep 2006 | A1 |
20060222445 | Chuang | Oct 2006 | A1 |
20060235371 | Wakamatsu et al. | Oct 2006 | A1 |
20060253078 | Wu et al. | Nov 2006 | A1 |
20060253079 | McDonough et al. | Nov 2006 | A1 |
20060253125 | Ignon | Nov 2006 | A1 |
20060264893 | Sage, Jr. et al. | Nov 2006 | A1 |
20060264926 | Kochamba | Nov 2006 | A1 |
20060269580 | Cole et al. | Nov 2006 | A1 |
20060278661 | Cooper et al. | Dec 2006 | A1 |
20070005078 | Hart et al. | Jan 2007 | A1 |
20070020321 | Redding et al. | Jan 2007 | A1 |
20070027411 | Ella et al. | Feb 2007 | A1 |
20070043382 | Cheney | Feb 2007 | A1 |
20070049901 | Wu et al. | Mar 2007 | A1 |
20070065515 | Key | Mar 2007 | A1 |
20070073327 | Giovannoli | Mar 2007 | A1 |
20070078290 | Esenaliev | Apr 2007 | A1 |
20070088245 | Babaev et al. | Apr 2007 | A1 |
20070088371 | Karasiuk | Apr 2007 | A1 |
20070093694 | Fassuliotis et al. | Apr 2007 | A1 |
20070123808 | Rhoades | May 2007 | A1 |
20070139630 | Kleman et al. | Jun 2007 | A1 |
20070149991 | Mulholland | Jun 2007 | A1 |
20070154502 | Hattendorf et al. | Jul 2007 | A1 |
20070156124 | Ignon et al. | Jul 2007 | A1 |
20070178121 | First et al. | Aug 2007 | A1 |
20070198031 | Kellogg | Aug 2007 | A1 |
20070232987 | Diaz et al. | Oct 2007 | A1 |
20070239079 | Manstein et al. | Oct 2007 | A1 |
20070239173 | Khalaj | Oct 2007 | A1 |
20070255355 | Altshuler et al. | Nov 2007 | A1 |
20070264625 | DeBenedictis et al. | Nov 2007 | A1 |
20070270738 | Wu et al. | Nov 2007 | A1 |
20080009802 | Lambino et al. | Jan 2008 | A1 |
20080015555 | Manstein et al. | Jan 2008 | A1 |
20080027328 | Klopotek et al. | Jan 2008 | A1 |
20080027518 | Island et al. | Jan 2008 | A1 |
20080091126 | Greenburg | Apr 2008 | A1 |
20080091179 | Durkin et al. | Apr 2008 | A1 |
20080103563 | Powell | May 2008 | A1 |
20080119781 | King | May 2008 | A1 |
20080132914 | Bossard et al. | Jun 2008 | A1 |
20080139974 | Da Silva | Jun 2008 | A1 |
20080146970 | Litman et al. | Jun 2008 | A1 |
20080154161 | Abbott | Jun 2008 | A1 |
20080154183 | Baker et al. | Jun 2008 | A1 |
20080161799 | Stangenes et al. | Jul 2008 | A1 |
20080188840 | Johnson et al. | Aug 2008 | A1 |
20080193493 | Rhoades | Aug 2008 | A1 |
20080200861 | Shalev et al. | Aug 2008 | A1 |
20080200863 | Chomas et al. | Aug 2008 | A1 |
20080208146 | Brandwein et al. | Aug 2008 | A1 |
20080208179 | Chan et al. | Aug 2008 | A1 |
20080214987 | Xu | Sep 2008 | A1 |
20080215068 | Hart et al. | Sep 2008 | A1 |
20080221548 | Danenberg et al. | Sep 2008 | A1 |
20080234626 | Chelak | Sep 2008 | A1 |
20080243039 | Rhoades | Oct 2008 | A1 |
20080287864 | Rosenberg | Nov 2008 | A1 |
20080300529 | Reinstein | Dec 2008 | A1 |
20080300552 | Cichocki et al. | Dec 2008 | A1 |
20090048557 | Yeshurun et al. | Feb 2009 | A1 |
20090053390 | Sakou et al. | Feb 2009 | A1 |
20090062815 | Karasiuk et al. | Mar 2009 | A1 |
20090099091 | Hantash | Apr 2009 | A1 |
20090099093 | Hantash | Apr 2009 | A1 |
20090118684 | Da Silva et al. | May 2009 | A1 |
20090124985 | Hasenoehrl et al. | May 2009 | A1 |
20090132012 | Shanks | May 2009 | A1 |
20090138026 | Wu | May 2009 | A1 |
20090171191 | Patrick et al. | Jul 2009 | A1 |
20090171194 | Patrick et al. | Jul 2009 | A1 |
20090177171 | Ignon et al. | Jul 2009 | A1 |
20090192442 | Ignon et al. | Jul 2009 | A1 |
20090222023 | Boone, III et al. | Sep 2009 | A1 |
20090254014 | Son | Oct 2009 | A1 |
20090299237 | Rhoades | Dec 2009 | A1 |
20100023003 | Mulholland | Jan 2010 | A1 |
20100036298 | Fuster | Feb 2010 | A1 |
20100045427 | Boone, III et al. | Feb 2010 | A1 |
20100048980 | De Jong et al. | Feb 2010 | A1 |
20100049177 | Boone, III et al. | Feb 2010 | A1 |
20100049210 | Boone, III et al. | Feb 2010 | A1 |
20100056847 | De Jong et al. | Mar 2010 | A1 |
20100063565 | Beerwerth et al. | Mar 2010 | A1 |
20100217357 | Da Silva | Aug 2010 | A1 |
20100305495 | Anderson et al. | Dec 2010 | A1 |
20110054490 | Hart | Mar 2011 | A1 |
20110060270 | Eppstein | Mar 2011 | A1 |
20110066162 | Cohen | Mar 2011 | A1 |
20110082415 | Ignon et al. | Apr 2011 | A1 |
20110067761 | King | Jun 2011 | A1 |
20110144410 | Kennedy | Jun 2011 | A1 |
20110190726 | Hantash et al. | Aug 2011 | A1 |
20110251523 | Kim | Oct 2011 | A1 |
20110264028 | Ramdas et al. | Oct 2011 | A1 |
20110270137 | Goren et al. | Nov 2011 | A1 |
20110270364 | Kreindel | Nov 2011 | A1 |
20110295273 | Waldron et al. | Dec 2011 | A1 |
20120022435 | Ignon et al. | Jan 2012 | A1 |
20120041338 | Chickering, III et al. | Feb 2012 | A1 |
20120041523 | Solomon et al. | Feb 2012 | A1 |
20120109041 | Munz | May 2012 | A1 |
20120109043 | Zhou et al. | May 2012 | A1 |
20120136374 | Karasiuk | May 2012 | A1 |
20120171636 | Groman | Jul 2012 | A1 |
20120259252 | Thorn-Leeson et al. | Oct 2012 | A1 |
20120289885 | Cottrell | Nov 2012 | A1 |
20120302929 | Tkachenko | Nov 2012 | A1 |
20130004230 | Kirk, III et al. | Jan 2013 | A1 |
20130018317 | Bobroff et al. | Jan 2013 | A1 |
20130066336 | Boone, III et al. | Mar 2013 | A1 |
20130085421 | Gillespie et al. | Apr 2013 | A1 |
20130096546 | Mirkov et al. | Apr 2013 | A1 |
20130096577 | Shadduck | Apr 2013 | A1 |
20130144207 | Gonon | Jun 2013 | A1 |
20130144280 | Eckhouse et al. | Jun 2013 | A1 |
20130158547 | David | Jun 2013 | A1 |
20130204238 | Lederman et al. | Aug 2013 | A1 |
20130226075 | Hennings et al. | Aug 2013 | A1 |
20130226269 | Eckhouse et al. | Aug 2013 | A1 |
20130261534 | Niezgoda et al. | Oct 2013 | A1 |
20130268032 | Neev | Oct 2013 | A1 |
20130296807 | Lintern et al. | Nov 2013 | A1 |
20130310906 | Neev | Nov 2013 | A1 |
20130317314 | Lampson | Nov 2013 | A1 |
20130345616 | Chang | Dec 2013 | A1 |
20140031801 | Giovannoli | Jan 2014 | A1 |
20140079686 | Barman et al. | Mar 2014 | A1 |
20140081251 | Giovannoli | Mar 2014 | A1 |
20140094718 | Feldman | Apr 2014 | A1 |
20140114234 | Redding, Jr. | Apr 2014 | A1 |
20140135798 | David | May 2014 | A1 |
20140234004 | Thorpe et al. | Aug 2014 | A1 |
20140243589 | Rowan | Aug 2014 | A1 |
20140316492 | Min et al. | Oct 2014 | A1 |
20140343481 | Ignon | Nov 2014 | A1 |
20140378887 | Chang et al. | Dec 2014 | A1 |
20150039060 | Paulussen et al. | Feb 2015 | A1 |
20150141877 | Feldman | May 2015 | A1 |
20150157496 | Horton et al. | Jun 2015 | A1 |
20150202007 | Mainstein et al. | Jul 2015 | A1 |
20150231379 | Ignon et al. | Aug 2015 | A1 |
20150272623 | Ignon et al. | Oct 2015 | A1 |
20150313993 | Bock | Nov 2015 | A1 |
20150351868 | Groman | Dec 2015 | A1 |
20160015962 | Maragheh et al. | Jan 2016 | A1 |
20160018100 | Batt et al. | Jan 2016 | A1 |
20160089525 | Grez et al. | Mar 2016 | A1 |
20160175609 | Dye et al. | Jun 2016 | A1 |
20160220849 | Knowlton | Aug 2016 | A1 |
20160235257 | Daffer | Aug 2016 | A1 |
20160250415 | Yagi et al. | Sep 2016 | A1 |
20160256671 | Ignon et al. | Sep 2016 | A1 |
20160270850 | Manstein et al. | Sep 2016 | A1 |
20160270851 | Moench et al. | Sep 2016 | A1 |
20160287333 | Morrison | Oct 2016 | A1 |
20160324578 | Manstein et al. | Nov 2016 | A1 |
20170043150 | Kim | Feb 2017 | A1 |
20170065829 | Ku | Mar 2017 | A1 |
20170106206 | Seckel | Apr 2017 | A1 |
20170128319 | Decaux et al. | May 2017 | A1 |
20170157419 | Jeong | Jun 2017 | A1 |
20170196759 | Palomaki et al. | Jul 2017 | A1 |
20170209894 | Sporrer | Jul 2017 | A1 |
20170252105 | Deem et al. | Sep 2017 | A1 |
20170291007 | Dubey et al. | Oct 2017 | A1 |
20170340356 | Presser et al. | Nov 2017 | A1 |
20170343308 | Wojciechowski, III et al. | Nov 2017 | A1 |
20180008500 | Anderson et al. | Jan 2018 | A1 |
20180140329 | Beijens et al. | May 2018 | A1 |
20180185675 | Kern et al. | Jul 2018 | A1 |
20180310979 | Peled et al. | Nov 2018 | A1 |
20180318568 | Ignon et al. | Nov 2018 | A1 |
20180326191 | Bansal et al. | Nov 2018 | A1 |
20190009110 | Gross et al. | Jan 2019 | A1 |
20190009111 | Myhr et al. | Jan 2019 | A1 |
20190070069 | Gertner et al. | Mar 2019 | A1 |
20190076193 | Clementi et al. | Mar 2019 | A1 |
20190083161 | Harle et al. | Mar 2019 | A1 |
20190133642 | Ignon et al. | May 2019 | A1 |
20190143089 | Ignon et al. | May 2019 | A1 |
20190151637 | Groop et al. | May 2019 | A1 |
20190168016 | Anderson et al. | Jun 2019 | A1 |
20190183562 | Widgerow | Jun 2019 | A1 |
20190209859 | Quisenberry et al. | Jul 2019 | A1 |
20190224501 | Burdette | Jul 2019 | A1 |
20190239939 | Boll et al. | Aug 2019 | A1 |
20190240110 | Sedic | Aug 2019 | A1 |
20190240502 | Anderson et al. | Aug 2019 | A1 |
20190257320 | Petit et al. | Aug 2019 | A1 |
20190274759 | Royon et al. | Sep 2019 | A1 |
20190275320 | Kim et al. | Sep 2019 | A1 |
20190366067 | Ginggen et al. | Dec 2019 | A1 |
20200009007 | Shadduck | Jan 2020 | A1 |
20200016342 | Ignon | Jan 2020 | A1 |
20200030627 | Eltorai et al. | Jan 2020 | A1 |
20200093945 | Jeong | Mar 2020 | A1 |
20200101312 | Pai et al. | Apr 2020 | A1 |
20200114116 | Dubey et al. | Apr 2020 | A1 |
20200121354 | Ginggen et al. | Apr 2020 | A1 |
20200171288 | Ignon et al. | Jun 2020 | A1 |
20200171289 | Ignon et al. | Jun 2020 | A1 |
20200179220 | Jablow | Jun 2020 | A1 |
20200206072 | Capelli et al. | Jul 2020 | A1 |
20200254273 | Jafari et al. | Aug 2020 | A1 |
20200275945 | Knowlton | Sep 2020 | A1 |
20200288843 | Verheem | Sep 2020 | A1 |
20200289161 | Scooros | Sep 2020 | A1 |
20200306555 | Ebbesson | Oct 2020 | A1 |
20200316270 | Dijkstra et al. | Oct 2020 | A1 |
20200330754 | Kim et al. | Oct 2020 | A1 |
20200338586 | Park | Oct 2020 | A1 |
20200367961 | Podmore et al. | Nov 2020 | A1 |
20200390468 | Alexander | Dec 2020 | A1 |
20210001148 | Verheem | Jan 2021 | A1 |
20210052292 | Karni | Feb 2021 | A1 |
20210085367 | Shadduck et al. | Mar 2021 | A1 |
20210128416 | Danto | May 2021 | A1 |
20210145479 | Ignon et al. | May 2021 | A1 |
20210154093 | Boone, III et al. | May 2021 | A1 |
20210154455 | Ignon et al. | May 2021 | A1 |
20210170150 | Hong et al. | Jun 2021 | A1 |
20210220631 | Ok et al. | Jul 2021 | A1 |
20210236342 | Long et al. | Aug 2021 | A1 |
20210236347 | Carver | Aug 2021 | A1 |
20210236836 | Schwarz et al. | Aug 2021 | A1 |
20210242657 | Yi et al. | Aug 2021 | A1 |
20210259914 | Holbert | Aug 2021 | A1 |
20210267625 | Carver | Sep 2021 | A1 |
20210268304 | Lee | Sep 2021 | A1 |
20210275406 | Danto | Sep 2021 | A1 |
20210282855 | Boinagrov et al. | Sep 2021 | A1 |
20210283421 | Kang et al. | Sep 2021 | A1 |
20210290430 | Kim | Sep 2021 | A1 |
20210330356 | Del Rosario et al. | Oct 2021 | A1 |
20210353922 | Ignon et al. | Nov 2021 | A1 |
20210361525 | Park et al. | Nov 2021 | A1 |
20210370049 | Moss et al. | Dec 2021 | A1 |
20210370089 | Anash | Dec 2021 | A1 |
20210393478 | Bhatti | Dec 2021 | A1 |
20210393974 | Kim et al. | Dec 2021 | A1 |
20210393975 | Eltorai et al. | Dec 2021 | A1 |
20210395071 | Zubrum et al. | Dec 2021 | A1 |
20210402208 | Edgar | Dec 2021 | A1 |
20220001198 | Lee | Jan 2022 | A1 |
20220001199 | Beerwerth et al. | Jan 2022 | A1 |
20220008122 | Johnston et al. | Jan 2022 | A1 |
20220032082 | Shenfarber et al. | Feb 2022 | A1 |
20220054189 | Wootten | Feb 2022 | A1 |
20220071491 | Bae et al. | Mar 2022 | A1 |
20220072332 | Park et al. | Mar 2022 | A1 |
20220087891 | Goodman et al. | Mar 2022 | A1 |
20220111198 | Jung | Apr 2022 | A1 |
20220117632 | Walker et al. | Apr 2022 | A1 |
20220125706 | Horinek et al. | Apr 2022 | A1 |
20220126014 | Cederna et al. | Apr 2022 | A1 |
20220133407 | Anderson et al. | May 2022 | A1 |
20220175443 | Slatkine et al. | Jun 2022 | A1 |
20220176092 | Quan et al. | Jun 2022 | A1 |
20220203112 | Iger et al. | Jun 2022 | A1 |
20220211424 | Wootten et al. | Jul 2022 | A1 |
20220211988 | Ignon et al. | Jul 2022 | A1 |
20220218562 | Capelli et al. | Jul 2022 | A1 |
20220226668 | Lee et al. | Jul 2022 | A1 |
20220233400 | Oh et al. | Jul 2022 | A1 |
20220241107 | Kim et al. | Aug 2022 | A1 |
20220241146 | Jeong | Aug 2022 | A1 |
20220268536 | Stephenson et al. | Aug 2022 | A1 |
20220287910 | Boone et al. | Sep 2022 | A9 |
20220312940 | Hong et al. | Oct 2022 | A1 |
20220362529 | Castro | Nov 2022 | A1 |
20220401714 | Quan et al. | Dec 2022 | A1 |
20220409276 | Choi | Dec 2022 | A1 |
20230000523 | Nicolas et al. | Jan 2023 | A1 |
20230012684 | Ignon et al. | Jan 2023 | A1 |
20230014299 | Lee, Jr. et al. | Jan 2023 | A1 |
20230018295 | Ignon et al. | Jan 2023 | A1 |
20230019979 | Deem et al. | Jan 2023 | A1 |
20230033217 | Ignon et al. | Feb 2023 | A1 |
20230033761 | Ignon et al. | Feb 2023 | A1 |
20230042047 | Kim et al. | Feb 2023 | A1 |
20230055346 | Fortkort et al. | Feb 2023 | A1 |
20230062185 | Nazarian et al. | Mar 2023 | A1 |
20230104221 | Aharon | Apr 2023 | A1 |
20230123145 | Ko | Apr 2023 | A1 |
20230158282 | Ignon et al. | May 2023 | A1 |
20240017046 | Nebrigic et al. | Jan 2024 | A1 |
20240075263 | Ignon et al. | Mar 2024 | A1 |
20240139482 | Ignon et al. | May 2024 | A1 |
Number | Date | Country |
---|---|---|
400305 | Dec 1995 | AT |
1014299 | May 1999 | AU |
2340154 | Sep 2002 | CA |
2784209 | Aug 2011 | CA |
3292006 | Apr 2003 | CN |
1708261 | Dec 2005 | CN |
107920948 | Apr 2018 | CN |
305941358 | Jul 2020 | CN |
306109314 | Oct 2020 | CN |
306995346 | Dec 2021 | CN |
308188687 | Aug 2023 | CN |
599521 | Jul 1934 | DE |
2415633 | Oct 1975 | DE |
3338057 | Aug 1984 | DE |
3421390 | Dec 1985 | DE |
234608 | Apr 1986 | DE |
3503343 | Aug 1986 | DE |
8330191 | Jun 1987 | DE |
3740902 | Dec 1988 | DE |
4237940 | May 1993 | DE |
29808395 | Aug 1998 | DE |
10-2004-015815 | Nov 2005 | DE |
8794184-0001 | Dec 2021 | EM |
8880371-0001 | May 2022 | EM |
015024621-0002 | Jun 2023 | EM |
0258901 | Sep 1987 | EP |
0479121 | Apr 1992 | EP |
0564392 | Mar 1993 | EP |
0784997 | Jul 1997 | EP |
1238643 | Apr 2000 | EP |
1453558 | Sep 2004 | EP |
2206483 | Jul 2010 | EP |
2544563 | Sep 2015 | EP |
2106780 | Mar 2016 | EP |
2865867 | May 2016 | EP |
3217899 | May 2016 | EP |
2240099 | Feb 2018 | EP |
2967633 | Apr 2018 | EP |
3302319 | Apr 2018 | EP |
3319573 | May 2018 | EP |
3340908 | Jul 2018 | EP |
2451367 | Jan 2020 | EP |
3388006 | Mar 2020 | EP |
2618797 | Apr 2020 | EP |
3237055 | Aug 2020 | EP |
3795204 | Mar 2021 | EP |
3437575 | Apr 2021 | EP |
1037776 | Apr 1998 | ES |
2712172 | May 1995 | FR |
2773461 | Jul 1999 | FR |
1372609 | Oct 1974 | GB |
2306351 | May 1997 | GB |
2585500 | Jan 2021 | GB |
6228949 | Mar 2022 | GB |
6228947 | Sep 2022 | GB |
553076 | Dec 1956 | IT |
1184922 | Mar 1985 | IT |
S55-034863 | Aug 1963 | JP |
S54-63580 | May 1979 | JP |
H05-042060 | Feb 1993 | JP |
1993-088552 | Dec 1993 | JP |
1997-294747 | Nov 1997 | JP |
2003-534881 | Nov 2003 | JP |
2003-339713 | Dec 2003 | JP |
2004-275721 | Oct 2004 | JP |
2006-503627 | Feb 2006 | JP |
2006-204767 | Oct 2006 | JP |
2012-527967 | Nov 2012 | JP |
2013-215621 | Oct 2013 | JP |
D1581877 | Jul 2017 | JP |
D1609357 | Jun 2018 | JP |
2018-527052 | Sep 2018 | JP |
D1675782 | Jan 2021 | JP |
20-0280320 | Jul 2002 | KR |
10-20070070173 | Jul 2007 | KR |
10-2018-0030607 | Mar 2018 | KR |
10-1836310 | Mar 2018 | KR |
301238287.0000 | Nov 2023 | KR |
301238288.0000 | Nov 2023 | KR |
D155201 | Aug 2013 | TW |
D176752 | Jun 2016 | TW |
D214226 | Sep 2021 | TW |
WO 1994024980 | Nov 1994 | WO |
WO 1997000707 | Jan 1997 | WO |
WO 1997011650 | Mar 1997 | WO |
WO 199923951 | May 1999 | WO |
WO 199937229 | Jul 1999 | WO |
WO 2000015300 | Mar 2000 | WO |
WO 200079540 | Dec 2000 | WO |
WO 200193931 | Dec 2001 | WO |
WO 2004108091 | Dec 2001 | WO |
WO 2003073917 | Sep 2003 | WO |
WO 2004037098 | May 2004 | WO |
WO 2004037287 | May 2004 | WO |
WO 2005061042 | Jul 2005 | WO |
WO 2005070313 | Aug 2005 | WO |
WO 2006018731 | Feb 2006 | WO |
WO 2006031413 | Mar 2006 | WO |
WO 2007114904 | Oct 2007 | WO |
WO 2008012324 | Jan 2008 | WO |
WO 2009086182 | Jul 2009 | WO |
WO 2009088884 | Jul 2009 | WO |
WO 2009097451 | Aug 2009 | WO |
WO 2010022396 | Feb 2010 | WO |
WO 2010068960 | Jun 2010 | WO |
WO 2010151704 | Dec 2010 | WO |
WO 2011006009 | Jan 2011 | WO |
WO 2011110840 | Sep 2011 | WO |
WO 2012131623 | Oct 2012 | WO |
WO 2012145667 | Oct 2012 | WO |
WO 2013030117 | Mar 2013 | WO |
WO 2014091035 | Jun 2014 | WO |
WO 2014151104 | Sep 2014 | WO |
WO 2016052818 | Apr 2016 | WO |
WO 2016106396 | Jun 2016 | WO |
WO 2017007939 | Jan 2017 | WO |
WO 2017111481 | Jun 2017 | WO |
WO 2021018765 | Feb 2021 | WO |
WO 2021113343 | Jun 2021 | WO |
WO 2022099318 | May 2022 | WO |
WO 2023039524 | Mar 2023 | WO |
WO 2023064718 | Apr 2023 | WO |
WO 2023164572 | Aug 2023 | WO |
Entry |
---|
Amazon.com: IeBilif Facial Skin Care Machine, posted Dec. 14, 2023 (retrieved online Mar. 29, 2024) from https://www.amazon.com/IeBillif-Equipment-Esthetician-Essential-supplies/d (2023). |
Amazon.com: Osaki LED Therapy Dome, posted date unavailable (retrieved online Mar. 29, 2024), from https://www.amazon.com/Osake-LED-Therapy-Dome/dp/BO8NN3BS7L (2024). |
“BeautyBio: GLOfacial Hydro-Infusion deep pore cleansing + Blue LED clarifying tool”, found online at amazon.com Sep. 26, 2023, ref. dated Nov. 15, 2022, retrieved https://www.amazon.com/GLOfacial-Hyrdo-Infusion-Deep-Cleansing-Clarifying/dp/B0BGJLMSZP/. |
Celluma LITE Compact LED Light Therapy Device fr Travel, posted date unavailable, (retrieved online Mar. 29, 2024), from https://www.celluma.com/products/celluma-lite (2024). |
Elipsa-LightSlim, posted date unavailable, (retrieved online Mar. 29, 2024), from https://www.lightslim.com/products/lightslim-elipsa (2024). |
“Healthline: What is a HydraFacial and how does it work”, found online at healthline.com Sep. 26, 2023, Ref. dated Dec. 9, 2020, https://www.healthline.com/health/what-is-hydrafacial. |
HydraFacial MD Karma Spa Lounge & Beauty Bar, posted date unavailable (retrieved online Mar. 29, 2024), from https://www.karmabeautybar.com/hydrafacial-md (2024). |
“InStyle: Why the HydraFacial is one of the most popular in-office treatments”, found online at instyle.com on Sep. 26, 2023, ref. dated Jun. 12, 2023, https://www.instyle.com/beauty/skin/hydrafacial-treatment-facts. |
“Microderm Glo: Glo Mini”, found online at microdermglo.com Sep. 26, 2023, ref. dated Sep. 27, 2019, https://www.microdermglo.com/collections/microdermabrasion-machines. |
Amazon, Fazjeune 7 Color LED Light, LED Face Mask Skin Rejevenation PDT Photon Facial Skin Care Mask Skin Tightening Lamp SPA Face Device Beauty Salon Equipment Anti-aging Remove Wrinkle, Customer reviewed on Sep. 2020, retrieved from internet at https://www.amazon.com/FAZJEUNE-Rejuvenation-Tightening-Equipment-Anti-aging/dp/B08B4M8RQQ/ref=psdc_11061121_t3_B08ZSPZSF4. |
Beautimate adjustable Hydra Needle Microneedling Serium Applicator, https://www.beautimate.com/products/adjustable-hydra-needle, first accessed Aug. 12, 2023. |
File History of Reissue U.S. Appl. No. 11/027,590, filed Dec. 29, 2004 (Reissue of U.S. Pat. No. 6,500,183, issued Dec. 31, 2002). |
File History of Reexamination No. 90/007,683 (Reexamination of U.S. Pat. No. 6,241,739, issued Jun. 5, 2001). |
File History of Reexamination No. 90/013,284, filed Jul. 2, 2014 (Reexamination of U.S. Pat. No. 6,241,739, issued Jun. 5, 2001). |
Cox III et al., Decreased Splatter in Dermabrasion, Arch Facial Plastic Surgery, Jan.-Mar. 2000, vol. 2, pp. 23-26. |
Ditre et al., Effect of a-hydroxy acids on photoaged skin: A pilot clinical, histologic, and ultrastructuralstudy, Journal of American Academy of Dermatology, Feb. 1996, vol. 34, No. 2, Part 1, pp. 187-195. |
Harris et al., Combining Manual Dermasanding with Low Strength Trichloroacetic Acid to ImproveAntinically Injured Skin, The Journal of Dermatologic Surgery and Oncology, Jul. 1994, vol. 20, No. 7, pp. 436-442. |
Hydrafacial® Tower—User guide. Edge Systems. Revised Jun. 23, 2016. p. No. 16. |
Hydrafacial Hydropeel Vortex Fusion Tips, https://mergesouq.com/products/hydrafacial-hydropeel-vortex-fusion-tips, first accessed Aug. 12, 2023. |
Microdermabrader Pepita Instruction Manual, Mattioli Engineering S.R.L., PEP_USA2.doc Rev 1.1, Sep. 29, 1997. |
Number | Date | Country | |
---|---|---|---|
20240033491 A1 | Feb 2024 | US |
Number | Date | Country | |
---|---|---|---|
60764668 | Feb 2006 | US | |
60755310 | Dec 2005 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 18094884 | Jan 2023 | US |
Child | 18487916 | US | |
Parent | 17165820 | Feb 2021 | US |
Child | 18094884 | US | |
Parent | 16517268 | Jul 2019 | US |
Child | 17165820 | US | |
Parent | 15660750 | Jul 2017 | US |
Child | 16517268 | US | |
Parent | 14700789 | Apr 2015 | US |
Child | 15660750 | US | |
Parent | 13267554 | Oct 2011 | US |
Child | 14700789 | US | |
Parent | 11392348 | Mar 2006 | US |
Child | 13267554 | US |